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Summary 
Drug discovery process is typically a lengthy and costly process. Target, 
efficacy and safety are the three major issues. Cheminformatics and bioinformatics 
tools are explored to increase the efficiency and reduce the cost and time of 
pharmaceutical research and development. This work represents computational 
approaches to address these issues. In the first study, a particular focus has been given 
to database developing of two web accessible databases:  therapeutic targets database 
(TTD) and Information of Drug Activity Database (IDAD). The updated TTD is 
intended to be a more useful resource in complement to other related databases by 
providing comprehensive information about the primary targets and other drug data 
for the approved, clinical trial, and experimental drugs. IDAD is a drug activity 
database of drug and clinical trial compounds. The integration of information from 
these two databases leads to analysis of properties of drug and clinical trials 
compounds. It shows that there are some differences between them in terms of 
properties. This could lead to a better understanding the reasons for failures of clinical 
trials in drug discovery and serve as guidelines for selection of drug candidates for 
clinical trials. The second focus was given to the use of machine learning 
classification method for virtual screening of pharmaceutical agents. This method was 
tested on several systems like Abl inhibitors and HDAC inhibitors. It is shown that 
Support Vector Machine (SVM) based virtual screening system combined with a 
novel putative negative generation method is a highly efficient virtual screening tool. 
SVM models showed a prediction accuracy for non-inhibitors around 50% for 
independent testing set, which were comparable against other results, while the 
prediction accuracy for non-inhibitors is >99.9%, which were substantially better than 
  vi 
the typical values of 77%~96% of other studies. This high prediction accuracy for 
non-inhibitors is favorable for screening of extremely large compound libraries. The 
last part was devoted to an acute toxicity classification system based on statistical 
machine learning methods.  Evaluation of acute toxicity is one of the big challenges 
faced by pharmaceutical companies and many administrative organizations now 
because acute toxicity study is widely needed but very costly. Legislation calls for the 
use of information from alternative non-animal approaches like in vitro methods and 
in silico computational methods. QSAR based approaches remain the current main in 
silico solutions to prediction of acute toxicities but the performance is not satisfactory. 
SVM was explored as a new computational method to address the current issues and 
make a breakthrough in prediction of diverse classes of chemicals. Studies show that 
SVM models have better prediction accuracies (overall ~85% and independent testing 
~70%) than previous studies in classification of acute and non acute toxic chemicals.  
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Chapter 1 Introduction 
Drug discovery process is typically a lengthy and costly process. Cheminformatics 
and bioinformatics tools are explored to increase the efficiency and reduce the cost 
and time of pharmaceutical research and development. This work on “database 
development and machine learning prediction of pharmaceutical agents” is one of 
such kind of strategy which is introduced in this chapter. This introduction chapter 
consists five parts: (1) Cheminformatics and bioinformatics in Drug Discovery 
(Section 1.1); (2) Database development in drug discovery (Section 1.2); (3) Virtual 
Screening of pharmaceutical agents (Section 1.3); (4) Classification of toxicity of 
pharmaceutical agents (Section 1.4); (5) Objectives and outlines (Section 1.5) 
 
1.1 Cheminformatics and bioinformatics in drug discovery 
A typical drug discovery process from idea to market consists of seven basic steps: 
disease selection, target selection, lead compound identification, lead optimization, 
preclinical trial evaluation, clinical trials, and drug manufacturing. It is a lengthy, 
expensive, difficult, and inefficient process with low rate of new therapeutic 
discovery. The whole process takes about 10-17 years, $800 million (as per 
conservative estimates), and has less than 10% overall probability of success1 (Figure 
1-1).  Compared to the huge R&D investment in implementing new technologies for 
drug discovery, return is insignificant. Figure 1-2 shows the number of new chemical 
entities (NCEs) in relation to research and development (R&D) spending since 1992.     
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Figure 1- 1 Drug discovery and development process 
 
 
Figure 1- 2 Number of new chemical entities (NCEs) in relation to research and 
development (R&D) spending (1992–2006). Source: Pharmaceutical Research 
and Manufacturers of America and the US Food and Drug Administration2. 
 
The major problems faced by current drug discovery efforts are ‘target’, ‘efficacy’ 
and ‘safety’ — drugs are limited to a few known classes of targets and increased 
numbers of disease and drug resistances problems force people to look for more 
targets; compounds selected to enter into the clinical phases may lose efficacy in the 
patients; safety issues make many promising potent drug candidates fail at the clinical 
trials.  
Chapter 1 Introduction 
 3 
In 1990s, the areas like molecular biology, cellular biology and genomics grew 
rapidly which helped in understanding disease pathways and processes into their 
molecular and genetic components to recognize the cause of malfunction precisely, 
and problematic point at which therapeutic intervention can be applied. Those 
technologies include DNA sequencing, microarray, HTS, combinatory chemistry, 
high throughput sequencing and etc. They have shown great potential for elimination 
of the bottleneck. For instance, DNA sequencing, high throughput sequencing of 
extensive genome and microarray tests have helped to decode various organisms and  
allow bioinformatics approaches to predict several new potential targets. The progress 
helped in finding many new molecular targets (from approximately 500 to more than 
10,000 targets)3. On the chemistry side, combinatory chemistry and HTS have made it 
possible to quickly identify potential leads from big compound libraries.  All these 
technologies generate a lot of biological and chemistry data which have been coined 
with the suffix -ome and –omics inspired by the terms genome and genomics after the 
completion of Human Genome Project. We have now entered into a post-genomics 
stage for drug discovery. A list of omics approaches like genomics, pharmacogenetics, 
proteomics, transcriptomics and toxicogenomics have been applied to various stages 
in drug discovery. The integration of these information and discovery of new 
knowledge become the major tasks of bioinformatics and cheminformatics.  
According to the definition, Cheminformatics is the use of computer and 
informational techniques, applied to a range of problems in the field of chemistry4, 5. 
Similarly, bioinformatics is the application of information technology and computer 
science to the field of molecular biology. The term bioinformatics was coined by 
Paulien Hogeweg. The main tasks that informatics handle are two things: from data to 
information and from information to knowledge. People have put in a lot of hope in 
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bioinformatics and cheminformatics. According to BCC research report, the 
worldwide value of bioinformatics is expected to increase from $1.02 billion in 2002 
to $3.0 billion in 2010, at an average annual growth rate (AAGR) of 15.8% (Figure 1-
3) 6. The use of bioinformatics in drug discovery is likely to reduce the annual cost by 
33%, and the time by 30% for developing a new drug. Bioinformatics and 
cheminformatics tools are developed which are capable to congregate all the required 
information regarding potential targets like nucleotide and protein sequencing, 
homologue mapping7, 8, function prediction9, 10, pathway information11, structural 
information12 and disease associations13, chemistry information. The availability of 
that information can help pharmaceutical companies in saving time and money on 
target identification and validation.  
  
Figure 1- 3 Worldwide value of bioinformatics Source: BCC Research6 
 
1.2 Database development in drug discovery 
Rapid development in new technology have accumulated huge amount of data. The 
vast amount of chemistry and biological data and their usage by scientists for research 
purpose are creating new challenges for the database development. Data are generally 
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collected from different sources like experiments, public databanks, proprietary data 
providers, biological, pharmacological, or simulation studies. These data can be of 
various types, including very organized data type like relational database tables and 
XML files, disorganized web pages or flat files, and small or large objects like three-
dimensional (3D) biochemical structures or images. Most of these data lack common 
data formats or the common record identifiers that are required for interoperability.  
More importantly, these data need to be validated, analyzed, simplified and finally, 
only useful information shall be provided to the final users. Furthermore, in order to 
support the various individual scientific tasks in a drug discovery workflow, it is 
useful for software packages to be integrated so as to provide a quick overview of the 
research progress and support for further decisions. Recent trend is that the databases 
should be accessible through web browser (Figure 1-4).  This web accessible feature 
has outstanding advantages over the local databases. Web accessible databases 
become instantly available to user though internet browsers. Current web interfaces of 
biological data sources generally provide many user-specified criteria as part of 
queries. With such capability, the accessibility of customized records from the query 
results becomes an easy process even for naive users.  
 
Figure 1-4 An illustrative schematic representation depicting data flow represented 
by arrows, from data capture mechanisms through an information factor 
framework to data access mechanisms (adopted from Waller et al14) . 
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Currently there are many public bioinformatics databases (Table 1-1) and 
cheminformatics databases (Table 1-2) that provide broad categories of medicinal 
chemicals, biomolecules or literature15.  In this work, a particular focus has been 
given to development of web accessible databases for therapeutic targets and drugs. 
Current target discovery efforts have led to the discovery of hundreds of successful 
targets (targeted by at least one approved drug) and >1,000 research targets (targeted 
by experimental drugs only) 16-19. There are several known target and drug databases 
including Therapeutic Target Database (TTD), Potential Drug Target Database 
(PDTD), BindingDB, DrugBank and etc. 
 
Table 1-1 Examples of well known bioinformatics databases 
Information Database 
Primary genomic data (complete 
genomes, plasmids, and protein 
sequences) 
National Center for Biotechnology Information (NCBI) 
GenBank, EBI-EMBL, DNA Databank of Japan (DDBJ) 
Annotated protein sequences  Swiss-Prot and TrEMBL and Protein Information Resource (PIR) 
Results of cross-genome 
comparisons 
 
COG/KOG (Clusters of Orthologous groups of proteins) 
and Kyoto Encyclopedia of Genes and Genomes 
(KEGG) orthologies 
Information on protein families and 
protein classification 
Pfam and SUPFAM, and TIGRFAMs 
 
Cross-genome analysis 
TIGR Comprehensive Microbial Resource (CMR) and 
Microbial Genome Database for Comparative Analysis 
(MBGD) 
Protein–protein interactions  DIP, BIND, InterDom, and FusionDB 
Metabolic and regulatory pathways  KEGG and PathDB 
Protein three-dimensional (3D) 
structures Protein Data Bank (PDB) 
Multiple information PEDANT 
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Table 1-2 Examples of chemical databases 
Company name Web address Number of compounds Description 
4SC  www.4sc.de 5,000,000 Virtual library; small-molecule drug candidates  
ACB BLOCKS  www.acbblocks.com/acb/bblocks.html  90,000 
Building blocks for 




index.php  18,000 
OmniProbeTM: peptide 
libraries; 8000 tripeptide, 




mnicore.htm  170,000 
Targeted libraries: protease, 
protein kinase, GPCR, steroid 





1,750,000 Combinatorial and parallel chemistry, building blocks, HTS  
Asinex  www.asinex.com/prod/index.html  150,000 
Platinum collection: drug-like 
compounds  
Asinex   250,000 Gold collection: drug-like compounds  
Asinex   5009 Targeted libraries: GPCR (16 different targets)  
Asinex   4307 Kinase-targeted library (11 targets)  
Asinex   1629 Ion-channel targeted (4 targets)  
Asinex   2987 Protease-targeted library (5 targets)  




l   
100,000 Diverse primary screening compounds  
BioFocus   ~16,000  SoftFocus: kinase target-directed libraries  






Odyssey II library: diverse and 
unique discovery library; more 
than 350 chemical families  




very/downloads/  >750,000  
Leadlike compounds for 
bioscreening  
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ChemStar  www.chemstar.ru/page4.htm  60,260 
High-quality organic compounds 
for screening  
ChemStar   >500,000  Virtual database of organic compounds  
COMBI-






“Pharma relevant”, discrete 
structures for multitarget 
screening purposes  
ComGenex   240 GPCR library  
ComGenex   2000 
Cytotoxic discovery library: very 
toxic compounds suitable for 
anticancer and antiviral 
discovery research  
ComGenex   5000 
Low-Tox MeDiverse: druglike, 
diverse, nontoxic discovery 
library  







Highly diverse combinatorial 
compound collections for lead 
discovery  
InterBioScreen  www.ibscreen.com/products.shtml  350,000 Synthetic compounds  
InterBioScreen   40,000 Natural compounds  
Maybridge plc  www.maybridge.com/html/m_company.htm  60,000 Organic druglike compounds  





180,000 MDL Drug Data Report database 
MicroSource 
Discovery  
Systems, Inc.  
www.msdiscovery.com/d
ownload.html  2000 
GenPlus: collection of known 
bioactive compounds NatProd: 
collection of pure natural 
products  
Nanosyn  www.nanosyn.com/thankyou.shtml  46,715 Pharma library  





/dcs/order_form.html  N/A  
Targeted library: GPCR and 
kinase  
Polyphor  www.polyphor.com 15,000 Diverse general screening library  
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Diverse library of drug-like 
compounds, selected  based on 
Lipinski Rule of Five  
Specs  www.specs.net 240,000 Diverse library  
Specs   10,000 World Diversity Set: pre-plateled library  
Specs   6000 Building blocks  
Specs   500 Natural products (diverse and unique)  




_discovery.html  25,000 
HitCREATE library: 






80,000 LeadQuest compound libraries  
ZINC http://zinc.docking.org 13,000,000 
13 million purchasable 
compounds from many 
compound suppliers  
 
1.3 Virtual screening of pharmaceutical agents 
Virtual screening (VS) is a computational technique used in drug discovery research. 
It involves rapid in silico assessment of large libraries of chemical structures in order 
to identify those structures that are most likely to bind to a drug target, typically a 
protein receptor or enzyme20, 21. VS has been extensively explored for facilitating lead 
discovery22-25, identifying agents of desirable pharmacokinetic and toxicological 
properties26, 27  and other areas. There are two broad categories of screening 
techniques: structure-based and ligand-based 28. Structure-based VS (SBVS) involves 
docking of a candidate ligand into a protein target followed by applying a scoring 
function to estimate the likelihood that the ligand will bind to the protein with high 
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affinity29, 30. SBVS need a protein 3D structure. On the contrast, ligand-based VS 
(LBVS) can be performed when there is little or no information available on the 
molecular target. LBVS methods include pharmacophore methods31 and chemical 
similarity analysis methods32. Figure 1-5 shows the general procedure used in SBVS 
and LBVS.  
 
 
Figure 1- 5 General procedure used in SBVS and LBVS (adopted from Rafael V.C. et 
al33). The left part is for SBVS and the right part is for LBVS. 
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Docking is most straightforward VS method and it is preferred by the chemists. The 
success of a docking program depends on two components: the search algorithm and 
the scoring function. Docking and scoring technology is applied at drug discovery 
process for three main purposes: (1) predicting the binding mode of a known active 
ligand; (2) identifying new ligands using VS; (3) predicting the binding affinities of 
related compounds from a known active series. Of these three challenges, the first one 
is the area where most success has been achieved and for the third one, none of the 
docking programs or scoring functions made a satisfactory prediction34. As compared 
with structure-based methods, LBVS methods including pharmacophore methods and 
chemical similarity analysis methods have shown better performance in terms of 
speed, yield and enrichment factor.  Hit Rate is defined as the relation between the 
number of true hits found in the hit list respect to the total number of compounds in 
the hit list; and the Enrichment factor (EF) is the Hit Rate divided by the total number 
of hits in the full database relative to the total number of compounds in the database.  
To improve the coverage, performance and speed of VS tools, machine learning (ML) 
methods, including SVM, neural network and etc,  have recently been used for 
developing LBVS tools35-42 to complement or to be combined with SBVS 22, 43-54 and 
other LBVS23, 55-58 tools. ML methods have been used as part of the efforts to 
overcome several problems that have impeded progress in more extensive 
applications of SBVS and LBVS tools22, 59 . These problems include the vastness and 
sparse nature of chemical space needs to be searched, limited availability of target 
structures (only 15% of known proteins have known 3D structures), complexity and 
flexibility of target structures, and difficulties in computing binding affinity and 
solvation effects.  ML methods have been  explored for developing such alternative 
VS tools35-37  because of their high speed60 and capability for covering highly diverse 
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spectrum of compounds 61. Han et al62 did a comparative study for reported 
performance of different VS methods in screening large libraries of compounds as 
shown in Table 1-3.  ML methods show good potential for a better performance at VS 
of extremely large libraries with over 1M compounds. The reported yield, hit-rate and 
enrichment factor of ML tools are in the range of 55%~81%, 0.2%~0.7% and 
110~795 respectively 36, 39, 41, compared to those of 62%~95%, 0.65%~35% and 
20~1,200 by SBVS tools 46, 47. Moreover, he also developed a new putative negative 
generation method in which negatives were generated from 3M PubChem compounds. 
With this method he significantly improved yield, hit-rate and enrichment factor to 
52.4%~78.0%, 4.7%~73.8%, and 214~10,543 respectively in screening libraries of 
over 1 million compounds. For SBVS methods, approaches of using additional filters 
are often required in order to further minimize the false positives.  One approach is 
the selection of top-ranked hits, which has been extensively used in LBVS 36, 37, 41, 42, 
63, 64 and SBVS 46, 48-50, 65, 66. The second approach is the elimination of potentially 
unpromising hits in pre-screening stage by using such filters as Lipinski’s rule of five 
67 47, and recognition of  pharmacophore 49 and specific chemical groups or interaction 
patterns46, 48, 52, 68. The last one is the combination of LBVS and SBVS methods. All 
these approaches take quite some time. However, they are not required for SVM 
based approaches which already have a low false positives rate. 
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Table 1-3 Comparison of the reported performance of different VS methods in screening large libraries of compounds (adopted from Han et 
al62). 
Type of VS method 







Compounds screened Virtual hits selected by 
VS method 




























libraries ( ≥1M) 
Docking + pre-
screening filter 
(2) 46, 47 
1M~2M 355~63
0 












375~4.5K 0.28%~3% 5~231 2%~ 30% 
 




libraries ( ≥1M) 
Machine learning 
- SVM (2)36, 39, 41 
2.5M 22~46 0.0009%~ 
0.0018% 









~0.07% 1.7K 1% 26~70 22%~ 55% 1.5%~ 4.1% 22~55 
Machine learning 





984 1% 131~710 44%~ 69% 14%~ 72% 44~69 
Machine learning 








5.1K 5% 65~972 14%~ 94% 1.2%~ 18.9% 3~19 
Machine learning 
– LMNB (1)39, 41 
172K 118 0.069% 1.7K 1% 19 16% 1% 15 
Machine learning 





984 1% 132~960 34%~ 94% 13%~ 98% 53~94 














































libraries ( ≥1M) 
Pharmacophore 













380K 30 0.0079% 6917 1.82% 23 76.7% 0.33 41.8 
Ligand-based VS, 
extremely large 






SVM62 2.986M 2351 0.076% 8157 0.27% 1833 78.0% 22.5% 296 
SVM62 2.986M 225 0.007% 160 0.0054% 118 52.4% 73.8% 10543 
SVM62 2.986M 37 0.0012% 299 0.01% 23 62.2% 7.7% 6417 
SVM62 2.986M 664 0.022% 9502 0.32% 442 66.6% 4.7% 214 
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As it is common for the pharmaceutical industry to screen >1 million compounds per 
high-throughput screening campaign 71.  A small rise in the hit rate will lead to 
hundreds or thousands compounds to test. Improvement in screening performance is 
therefore very significant. We want to further improve SVM based VS as a well 
accepted VS method like docking. Current models were generated by using two-tier 
supervised classification SVM methods 35-37, 39-42, 72. The inactive compounds in these 
models have been collected from up to a few hundred known inactive compounds 
or/and putative inactive compounds from up to a few dozen biological target classes 
in MDDR database 35-37, 39-42, 72, which may not always be sufficient to fully represent 
inactive compounds in the vast chemical space, thereby making it difficult to 
optimally minimize false hit prediction rate of ML models. Han et al62  has 
demonstrated the potential of putative negatives generation method in helping to 
increase the performance of SVM based VS methods. We will carry on the study to 
further improve the method to generate more diverse negatives for training. Besides 
SVM, some other common ML methods include artificial neural network (ANN), 
probabilistic neural network (PNN), k nearest neighbor (k-NN), C4.5 decision tree 
(C4.5DT), linear discriminate analysis (LDA) and logistic regression (LR) were used.  
Some of these methods will be explained in Chapter 2 and attempted for comparison. 
Several types of pharmaceutical agents, including Abl kinase inhibitors, HDAC 
inhibitors (HDACi) will be investigated. Moreover, our SVM based VS system is also 
evaluated in terms of prediction on novel types structures because it is also one goal 
of VS28. 
 
Chapter 1 Introduction 
 16 
1.4 Classification of acute toxicity of pharmaceutical agents 
Toxicology is an important scientific discipline that impacts various practical aspects 
of daily life. Pharmaceuticals, personal health care products, nutritional ingredients 
and products of the chemical industries are all potential hazards and need to be 
assessed. There are various types of toxicities studies including acute toxicity, 
genotoxicity, mutagenicity, carcinogenicity, and etc. The information generated from 
toxicity studies is used in hazard identification and risk management in the context of 
production, handling, and use for various chemicals. Toxicological tests for these 
products are costly, frequently use laboratory animals and are time-consuming.  
Evaluation of toxicities is one of the big challenges faced by pharmaceutical 
companies and many administrative organizations including US Food and Drug 
Administration, European Union member countries, the organization for economic 
cooperation and development and other regulated communities. Taking these 
concerns into consideration, the legislations in various countries have called for the 
use of information from alternative (non-animal) approaches like in vitro methods, 
toxicogenomics methods or any computational approaches, as a means of identifying 
the presence or absence of potential toxicity issues of the substances. Commercial 
software for toxicity predictions are generally divided into two main categories, 
knowledge-based and statistically based.  Table 1-4 lists current commercially 
available software for prediction of various toxicological endpoints. For a predictive 
software, a good performance with specificity (percentage of true negatives predicted 
as negative) >=85% and sensitivity (percentage of true positives predicted as 
positives) >=85%  and false positives (true negatives predicted positive) <15% has 
been sought73.  This has been achieved for predictions of carcinogenicity74, 75, genetic 
toxicity76, reproductive and developmental toxicity77, and MRDD78, 79. However, for 
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acute toxicity, it remains still a challenge. It is because the nature of acute toxicity is 
very complicated. There are many types of toxic mechanisms. Moreover, acute 
toxicity is always connected to Absorption, Distribution, Metabolism, and Excretion 
(ADME). It could be affected by many factors, for instance, local and/or target-organ 
specific effects, bioavailability of the compound (absorption, tissue distribution and 
elimination) and its metabolism (both bioactivation and detoxification). Quantitative 
Structure-Activity Relationship (QSAR) remains the primary approach for prediction 
of acute toxicities80, 331. TOPKAT81 and MCASE82-88 are built on a collection of class-
specific QSARs. New computational methods are sought to address the current issues 
and make a breakthrough in prediction of diverse classes of chemicals.   
 
Table 1-4 Commercially available software for prediction of toxicity (adopted from 
Zmuidinavicius, D. et al80 ). 
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database of 150K substances for 
various endpoints and routes 
93, 94 
 












Mammalian acute toxicity, 
genotoxicity, 
organ-specific health effects 
80, 95, 
96 
1.5 Objectives and outline 
Overall, there are three major objectives for this work: 
1. To develop a database with good storing, managing, integration and 
providing the customized chemistry and biological information data of therapeutic 
targets and drugs; 
2. To develop a SVM based LBVS system and test its application for 
identification of inhibitors for several therapeutic targets; 
3. To apply machine learning approaches to screen acute toxicity issues 
in early drug discovery process; 
The complete outline of this thesis is as follows:  
In Chapter 1, an introduction to cheminformatics and bioinformatics to drug 
discovery process is described. Different VS methods are compared. At last, our SVM 
base VS system is described. 
In Chapter 2, methods used in this work are described. In particular, the 
dataset quality analysis, the statistical molecular design, the molecular descriptors, the 
putative negatives generation process, various statistical learning methods used in this 
work, and the model evaluation methods are presented in more detail.  
Chapter 3 is devoted to databases development for therapeutic targets and 
drugs including updating of TTD and building of IDAD. 
Chapter 4 to 5 are devoted to the application of our SVM based VS system for 
pharmaceutical agents like (i) Abl inhibitor, (ii) HDACi, In these chapters, SVM 
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based VS system combined with a novel putative negative generation method is 
evaluated as a highly efficient VS tool. 
In Chapter 6, SVM models built on large number diverse pharmaceutical 
agents were developed for the prediction of acute toxicity.  
Finally, in the last chapter, Chapter 7, major findings and contributions of 
current work for VS of pharmaceutical agent were discussed. Limitations and 
suggestions for future studies were also rationalized.  
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Chapter 2 Methods  
2.1 Database development 
Database is an organized collection of data and relationships among the data 
items. Generally database development is a complicated and time-consuming process, 
including collection of related information, design of database scheme and data 
integration, design of database interface and implementation of database functions.  
 
2.1.1 Data collection 
Normally, a knowledge-based database is supposed to provide enough domain 
knowledge around a specific subject together with information of related subjects. For 
instance, TTD provides users information of drugs, the corresponding targets, and 
targeted diseases. Data collection of these information can be done by various ways 
like manual data collection from literature, experiments or software output, part of the 
data taken from other databases, customized data, text mining by programs, and so on. 
Literatures are typically unstructured data sources. Names of the subject that are 
stored in different synonymous terms, various abbreviations, or totally different 
expressions are difficult to be recognized by automatic language processing. It is hard 
to invent a fully automated literature information extraction system to gather useful 
information from literature efficiently. Manual data collection from literature or 
manual curation of collected data is considered of the best quality. However, it is too 
time consuming and expensive97. A number of solutions for this problem are in 
practice. Data curation and annotation can be done in collaboration with other groups 
or providing online facility to edit or submission of data98.  Moreover, simple 
automated text retrieval programs developed in PERL are quite useful in retrieving 
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information from literatures that contained the key word related to searching the 
subject via Medline99. 
 
2.1.2 Data Integration 
Data integration is necessary where data from different sources need to be 
standardized before using it in making databases. It becomes a big challenge to get 
biological and chemical data from varied sources integrated to a single database. 
Improper integration can lead to loss of some part of data or even can introduce 
mistakes. The correct way of data integration for biological databases can generally 
be divided into two parts: (i) syntactic integration in which data from different sources 
and of different file formats are standardized to have single file format and (ii) 
semantic integration in which data from different databases are formalized to have a 
relational schema which holds relational tables and integrity constraints.  For syntactic 
integration, the standardized file format to which other data should be converted is 
generally XML. In addition to the abovementioned ways of data integration, data can 
be integrated manually as well. It is generally achieved through scripting languages 
like Perl or Python. It is very time consuming and tedious to do that but sometimes it 
becomes indispensable. 
There are a number of different ways to construct database to store and present data. 
Some of the more common database types include hierarchical database, object 
database and relational database. Relational database is the most often used database 
type now which arranges data in a tabular format. A relational database creates formal 
definitions of all the included items in a database, setting them out in tables, and 
defines the relationship among them. Using IDs or keys, the tables can be related 
between each other. Such database is called 'relational' because they explicitly define 
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these connections. The relational database model has been used in our TTD and 
IDAD databases. In the tables of relational database, certain fields may be designated 
as keys, by which the separated tables can be linked together for facilitating to search 
specific values of that field. Primary key uniquely identifies each record in the table. 
Foreign key can be used to cross-reference tables. Most relational databases now 
make use of Structured Query Language (SQL) to handle queries. SQL is widely used 
by relational databases to define queries and help to generate reports. SQL has 
become a dominant standard in the world of database development, since it allows 
developers to use the same basic constructions to query data from a wide variety of 
systems. By using relational database software (e.g. Oracle, Microsoft SQL Server) or 
even personal database systems (e.g. Access), the relational database can be organized 
and managed effectively. This kind of data storage and retrieval system is called 
Database Management System (DBMS). An Oracle 9i DBMS is used to define, create, 
maintain and provide controlled access to our databases and the repository. All entry 
data from the related tables described in previous section are brought together for user 
display and output using SQL queries.  
 
2.1.3 Database interface 
Web interface, or web accessible database, is currently a popular interface that user 
sees and interacts with the database.  The web interface should be very convenient to 
understand and user should have certain level of flexibility of getting customized data. 
Dynamic pages are the type of web pages which presents different web page content 
to different user according to the form submitted by them which may differ in 
keywords or selection of features. In this work ASP and JSP technologies are used for 
server side dynamic web page creation and JavaScript is used for client side dynamic 
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web page creation.  Server side dynamic web page creation over database involves 
submission of user supplied query to web server which further interacts with database 
software such as MySQL and Oracle. In contrast, client side dynamic web page 
creation does not include interaction with web server. The client side technology uses 
users’ internet browsers e.g. Microsoft Internet Explorer, Mozzila Firefox and Google 
Chrome to run its code and display the data. The client side dynamic web page is thus 
very simple and generally used to present data in beautiful manner and provides helps 
about the content such as change in color or short string giving help when mouse is 
place on some part of the content. 
 
2.1.4 Applications 
Besides these, there are often some web application provided for users to analyze 
data, extract information from other sources, customized query and download, result 
summary, and etc. These biological and chemical applications include some well 
known programs like  sequence similarity search using BLAST, chemical structure 
similarity search  using fingerprint, text similarity search using regular expression and 
etc. The BLAST programs is used to do sequence-similarity searches against protein 
and nucleotide databases, which align the input sequence with database on the server 
with great speed. It is one of the most widely used programs for data mining in 
genomics and proteomics. The result of BLAST is normally pairwise alignment, 
multiple sequence alignment formats, hit table and a report explaining hits by 
taxonomy. The NCBI BLAST programs are also available freely to download and 
implement in user’s web application. Chemical similarity search uses fingerprint 
representing chemical compound in a binary format of differing length to compare to 
fingerprints stored of other compounds in database based on Tanimoto coefficient. 
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Text matching is generally achieved by using regular expression which can be defined 
as sequence of characters that depict a pattern in text. Perl is a very popular 
programming language with regular expression based search capability because of its 
easiness, speed and flexibility to perform same thing in many ways. In regular 
expression, metacharacters (like ^, &, (, ), * etc.) are utilized  to construct efficient 




2.1.5 Database Development of TTD and IDAD 
The development of TTD and IDAD has seen a good application of the knowledge 
listed in the above sections. First, various information about drugs and targets was 
collected from literatures, books and web. This was followed by a time-consuming 
and tedious information curation process to ensure correct information is stored in the 
databases. Design of database scheme and data integration is the second challenge. 
Using relational database construction software (e.g. Oracle, Microsoft SQL Server) 
or even the personal database systems (e.g. Access, Fox), the Oracle 9i based 
relational database management systems have been built to organize and manage the 
various information needed for TTD and IDAD. All entry data from the related tables 
described can therefore be brought together for user display and output using SQL 
queries. Figure 2-1 is a general logical view of databases (TTD, IDAD) we developed. 
It shows the organization of relevant data into relational tables. Separate tables are 
linked together using primary and foreign keys. In tables of our databases, there are 
two foreign keys: Data type ID and Reference ID. As shown in Figure 2-1, a 
connection between a pair of tables is established by using a foreign key. The two 
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foreign keys make three tables relevant. These tables have a one-to-many relationship 
between each others.  Design of database interface and implementation of database 
functions is the last hard part of work. By integrating databases and web sites using 
ASP web programming language, users and clients can open up possibilities for data 
access and dynamic web content. A basic integrated information system of our 
pharmainformatics database for TTD or IDAD is thus constructed. Furthermore, some 
well known web applications like BLAST or customized applications developed by 
our group like similarity search tool are integraded to the database system to provide 
for users conveniences to analyze data, extract information from other sources, 
customized query and download, result summary, and etc. This is the whole process 
of development process for the two databases TTD and IDAD. 
 
Figure 2- 1 Logical view of the database 
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2.2 Datasets  
2.2.1 Quality analysis  
The development of reliable pharmacological properties classification models 
depends on the availability of high quality pharmacological property descriptor data 
with low experimental errors101. Dataset used for machine learning classification is of 
utmost importance. Factors like quality, size and relevance of the dataset can affect 
machine learning process greatly. Dataset quality is generally assessed at the time of 
data collection. In SVM based VS of compound inhibitors, in vitro enzymatic test 
data are used. In toxicity prediction, in vivo LD50 data are used. There are usually 
small variances in different in vitro data for same compound but big variances in 
different in vivo LD50 data. This is due to the complicated nature of in vivo 
experiments. This will lead to some problems for building SVM models when in vivo 
LD50 datasets from different sources are combined for training. To improve the data 
quality for training, some additional processing is needed, for instance, removal of 
inconsistent data, excluding some potential data points with cut-offs.  
 
2.2.2 Determination of structural diversity 
Structural diversity of a collection of compounds can be evaluated by using the 
Diversity Index (DI), which is the average value of the similarity between pairs of 










       (1) 
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where ),( jisim  is a measure of similarity between compounds i  and j , D is the 
dataset and |D| is set cardinality which is a measure of the number of elements of the 
set. The dataset is more diverse when DI approaches 0. 
Tanimoto coefficient103 is used to compute ),( jisim  in this study, 























                    (2) 
where k  is the number of descriptors calculated for the compounds in the dataset. A 
compound i is considered to be similar to a known active j in the active dataset if the 
corresponding sim(i,j) value is greater than a cut-off value.  
 
 
2.3 Molecular descriptors  
2.3.1 Types of molecular descriptors  
Molecular descriptors have been extensively used in deriving structure-activity 
relationships 104, 105, quantitative structure activity relationships 106, 107, and machine 
learning prediction models for pharmaceutical agents 108-115. A descriptor is the final 
result of a logical and mathematical procedure which transforms chemical information 
encoded within a symbolic representation of a compound into a useful number or the 
result of some standardized experiment. A number of programs e.g. DRAGON116, 
Molconn-Z117, MODEL118, Chemistry Development Kit(CDK) 119, 120, JOELib 121, and 
Xue descriptor set 112 are available to calculate chemical descriptors. These methods 
can be used for deriving >3,000 molecular descriptors including constitutional 
descriptors, topological descriptors, RDF descriptors 122, molecular walk counts 123, 
3D-MoRSE descriptors 124, BCUT descriptors 125, WHIM descriptors 126, Galvez 
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topological charge indices and charge descriptors 127, GETAWAY descriptors 128, 2D 
autocorrelations, functional groups, atom-centred descriptors, aromaticity indices 129, 
Randic molecular profiles 130, electrotopological state descriptors 131, linear solvation 
energy relationship descriptors 132, and other empirical and molecular properties. Not 
all of the available descriptors are needed for representing features of a particular 
class of compounds. Moreover, without properly selecting the appropriate set of 
descriptors, the performance of a developed machine learning VS tool may be 
affected to some degrees because of the noise arising from the high redundancy and 
overlapping of the available descriptors. In this work, the 2D structure of each of the 
compounds was generated by using ChemDraw133 or downloaded from other database 
like PubChem134 and was subsequently converted into 3D structure by using 
CORINA135. A total of 525 chemical descriptors were derived using program 
developed by our group136, of  which either entire or part of the descriptors were used 
in this work. In the putative negative generation method, a set of 100 molecular 
descriptors were further selected from these descriptors by discarding those that were 
redundant and unrelated to the problem studied here. These 100 descriptors are listed in 
Table 2-1.  
 
Table 2- 1 Descriptors used in this study 
Descriptor Class No. of 
descriptors 
Descriptors 
Simple molecular properties 
137 138 
13 Molecular weight, Sanderson electronegativity 
sum, no. of atoms, bonds, rings, H-bond 
donor/acceptor, rotatable bonds, N or O 
heterocyclic rings, no. of C, N, O atoms. 
Charge descriptors138 10 Relative positive/negative charge, 0-2nd 
electronic-topological descriptors, electron 
charge density connectivity index, total absolute 
atomic charge, charge polarization, topological 
electronic index, local dipole index. 
Molecular connectivity and 
shape descriptors137, 139 
37 1-3rd order Kier shape index, Schultz/Gutman 
molecular topological index, total path count, 1-6 
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molecular path count, Kier molecular flexibility, 
Balaban/Pogliani/Wiener/Harary index, 0th edge 
connectivity, edge connectivity, extended edge 
connectivity, 0-2nd valence connectivity, 0-2nd 
order delta-chi index, 0-2nd solvation 
connectivity, 1-3rd order kappa alpha shape, 
topological radius, centralization, graph-
theoretical shape coefficient, eccentricity, 
gravitational topological index. 
Electrotopological state 
indices137, 140 
40 Sum of E-state of atom type sCH3, dCH2, ssCH2, 
dsCH, aaCH, sssCH, dssC, aasC, aaaC, sssC, 
sNH3, sNH2, ssNH2, dNH, ssNH,, aaNH, dsN, 
aaN, sssN, ddsN, aOH, sOH, ssO, sSH, H-bond 
acceptors, all heavy/C/hetero atoms, Sum of H 
E-state of atom type HsOH, HdNH, HsSH, 
HsNH2, HssNH, HaaNH, HtCH, HdCH2, HdsCH, 




Chemical descriptors are normally scaled before they can be employed for machine 
learning. Scaling of chemical descriptors ensures that each of descriptor have 
unbiased contribution in creating the prediction models141.  Scaling can be done by 
number of ways e.g. auto-scaling, range scaling, Pareto scaling, and feature weighting 
142, 143. In this work, range scaling is used to scale the chemical descriptor data. Range 
scaling is done by dividing the difference between descriptor value and the minimum 
value of that descriptor with the range of that descriptor:  
𝑑𝑑𝑖𝑖𝑖𝑖
𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑑𝑑 = 𝑑𝑑𝑖𝑖𝑖𝑖 −𝑑𝑑𝑖𝑖 ,𝑚𝑚𝑖𝑖𝑚𝑚
𝑑𝑑𝑖𝑖 ,𝑚𝑚𝑠𝑠𝑚𝑚 −𝑑𝑑𝑖𝑖 ,𝑚𝑚𝑖𝑖𝑚𝑚                                  (3) 
where 𝑑𝑑𝑖𝑖𝑖𝑖𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑑𝑑 , 𝑑𝑑𝑖𝑖𝑖𝑖 ij , 𝑑𝑑𝑖𝑖,𝑚𝑚𝑠𝑠𝑚𝑚 and 𝑑𝑑𝑖𝑖,𝑚𝑚𝑖𝑖𝑚𝑚 are the scale descriptor value of compound i, 
absolute descriptor value of compound i, maximum and minimum  values of 
descriptor  j respectively. The scaled descriptor value falls in the range of 0 and 1.  
 
 
2.4 Statistical learning methods  
Machine learning classification methods employ computational and statistical methods to 
construct mathematical models from training samples which is used to classify 
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independent test sample. The training samples are represented by vectors which can 
binary, categorical or continuous.  Machine learning can be divided into two types: 
Supervised and Unsupervised. Supervised machine learning, as the name indicates, 
generally needs feeding which generally involve already labeled or classified training 
data. Example of supervised machine learning includes SVM, ANN, Decision tree 
learning, Inductive logic programming, Boosting, Gaussian process regression etc. 
Unsupervised machine learning, as the name indicates, gets unlabeled training data and 
the learning task involve to find the organization of data. Examples of unsupervised 
machine learning include Clustering, Adaptive Resonance Theory, and Self Organized 
Map (SOM). Some of machine learning methods employed in this work are SVM, PNN, 
kNN. They are explained below in subsequent sub sections. For a comparative study, 
Tanimoto similarity searching method is also introduced.  Websites for codes of some 
machine learning methods are given in Table 2-2.  
 
Table 2- 2 Websites that contain codes of machine learning methods 
BKD 







k Nearest Neighbor  http://www.cs.cmu.edu/~zhuxj/courseproject/knndemo/KNN.html 
PERL Module for 
KNN http://aspn.activestate.com/ASPN/CodeDoc/AI-Categorize/AI/Categorize/kNN.html 
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NeuralWorks Predict http://www.neuralware.com/products.jsp 
NeuroShell Predictor http://www.mbaware.com/neurpred.html 
SVM 
SVM light http://svmlight.joachims.org/ 
LIBSVM http://www.csie.ntu.edu.tw/~cjlin/libsvm/ 
mySVM http://www-ai.cs.uni-dortmund.de/SOFTWARE/MYSVM/index.html 
BSVM  http://www.csie.ntu.edu.tw/~cjlin/bsvm/ 
SVMTorch http://www.idiap.ch/learning/SVMTorch.html 
 
2.4.1 Support vector machines method 
The process of training and using a SVM VS model for screening compounds based 
on their molecular descriptors is schematically illustrated in Figure 2-2. SVM is 
based on the structural risk minimization principle of statistical learning theory144, 145, 
which consistently shows outstanding classification performance, is less penalized by 
sample redundancy, and has lower risk for over-fitting146, 147. In linearly separable 
cases, SVM constructs a hyper-plane to separate active and inactive classes of 
compounds with a maximum margin. A compound is represented by a vector xi 
composed of its molecular descriptors. The hyper-plane is constructed by finding 
another vector w and a parameter b that minimizes 2w  and satisfies the following 
conditions: 
 
, o  iiby w
 Class 1 (active)   (4) 
 
, o  iiby w
 Class 2 (inactive)   (5) 
where yi is the class index, w is a vector normal to the hyperplane, /b w  is the 
perpendicular distance from the hyperplane to the origin and 2w  is the Euclidean 
norm of w. Base on w and b, a given vector x can be classified by f(x) =
[()]signb w
.  A positive or negative f(x) value indicates that the vector x belongs 
to the active or inactive class respectively.  
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In nonlinearly separable cases, which frequently occur in classifying compounds of 
diverse structures72, 148-154, SVM maps the input vectors into a higher dimensional 
feature space by using a kernel function K(xi, xj). We used RBF kernel  
2 2/ 2( , ) j ii jK e
σ− −= x xx x which has been extensively used and consistently shown better 
performance than other kernel functions155-157. Linear SVM can then applied to this 
feature space based on the following decision function  
0
1




f sign y K bα
=
= +∑x x x , where the coefficients αi0 and b are determined by 
maximizing the following Langrangian expression: 
1 1 1
1 ( , )
2
l l l
i i j i j i j
i i j
y y Kα α α
= = =
−∑ ∑∑ x x  







0α . A positive or negative f(x) value 
indicates that the vector x is an inhibitor or non-inhibitor respectively. For the SVM 
model in this study, hard margin SVM was used and gamma was scanned for the best 
performing model. Software LibSVM158, an integrated software for support vector 
classification, regression and distribution estimation, was chosen to do the machine 
learning in this work. 
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Figure 2- 2 Schematic diagram illustrating the process of the training a prediction 
model and using it for predicting active compounds of a compound class from their 
structurally-derived properties (molecular descriptors) by using SVM. A, B, E, F and 
(hj, pj, vj,…) represents such structural and physicochemical properties as 
hydrophobicity, volume, polarizability, etc. 
     
Chapter 2 Methods 
 34 
2.4.2 K-nearest neighbor method 
k-NN measures the Euclidean distance 2iD = −x x  between a compound x and 
each individual inhibitor or non-inhibitor xi in the training set159. A total of k number 
of vectors nearest to the vector x are used to determine the decision function f(x): 
1






← ∑x x                                                        (6) 
where ( , ) 1 if  and ( , ) 0 if a b a b a b a bδ δ= = = ≠  , argmax is the maximum of the 
function, V is a finite set of vectors {v1,...,vs}  and ˆ ( )f x  is an estimate of f(x). Here 
estimate refers to the class of the majority compound group (i.e. inhibitors or non-
inhibitors) of the k nearest neighbors.  
 
2.4.3 PNN method 
PNN is a form of neural network that classifies objects based on Bayes’ optimal 
decision rule160 ( ) ( )i i i j j jh c f h c f>x x , where hi and hj are the prior probabilities, ci and 
cj are the costs of misclassification and fi(x) and fj(x) are the probability density 
function for class i and j respectively. A compound x is classified into class i if the 
product of all the three terms is greater for class i than for any other class j (not equal 
to i). In most applications, the prior probabilities and costs of misclassifications are 
treated as being equal. The probability density function for each class for a univariate 
case can be estimated by using the Parzen’s nonparametric estimator161. 
1







= ∑ x xx         (7) 
where n is the sample size, σ is a scaling parameter which defines the width of the 
bell curve that surrounds each sample point, W(d) is a weight function which has its 
largest value at d = 0 and (x – xi) is the distance between the unknown vector and a 
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vector in the training set. The Parzen’s nonparametric estimator was later expanded 










g x x W
nσ σ σ σ=
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= ∑K KK     (8) 
The Gaussian function is frequently used as the weight function because it is well 
behaved, easily calculated and satisfies the conditions required by Parzen’s estimator. 
Thus the probability density function for the multivariate case becomes 
2
1 1








= −   
 
∑ ∑x       (9) 
The network architectures of PNN are determined by the number of compounds and 
descriptors in the training set. There are 4 layers in a PNN. The input layer provides 
input values to all neurons in the pattern layer and has as many neurons as the number 
of descriptors in the training set. The number of pattern neurons is determined by the 
total number of compounds in the training set. Each pattern neuron computes a 
distance measure between the input and the training case represented by that neuron 
and then subjects the distance measure to the Parzen’s nonparametric estimator. The 
summation layer has a neuron for each class and the neurons sum all the pattern 
neurons’ output corresponding to members of that summation neuron’s class to obtain 
the estimated probability density function for that class. The single neuron in the 
output layer then estimates the class of the unknown compound x by comparing all 
the probability density function from the summation neurons and choosing the class 
with the highest probability density function.  
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2.4.4 Tanimoto similarity searching method 
Compounds similar to at least one compound in a training dataset can be identified 
by using the Tanimoto coefficient sim(i,j) 163.  The equation for calculating tanimoto 
coefficient has been explained in Section 2.2.2. In this work, the similarity search was 
conducted for MDDR compounds. Therefore, in computing sim(i,j), the molecular 
descriptor vectors xis were scaled with respect to all of the MDDR compounds. The 
cut-off values for similarity compounds are typically in the range of 0.8 to 0.9 164, 165. 
A stricter cut-off value of 0.9 was used in this work. 
 
2.5 Statistical learning methods model optimization, validation and 
performance evaluation 
2.5.1 Model validation and parameters optimization 
Different Statistical learning methods (SLMs) have types of parameters that must be 
optimized. In this work SVM is trained by using a Gaussian radian basis kernel 
function which has an adjustable parameter gamma. For PNN, the only parameter to 
be optimized is a scaling parameter σ. In kNN, the optimum number of nearest 
neighbors, k, needs to be derived for each training set. Optimization of the parameter 
for each of these SLMs is conducted by scanning the parameter through a range of 
values. The set of parameters that produces the best pharmacological property 
prediction model, which is determined by using cross-validation methods, such as 5-
fold cross-validation, 10-fold cross-validation or a modeling testing set, is used to 
construct a final prediction model which is then further validated to ensure that it is 
valid and useful for further prediction. One of the usual ways to assess or to find the 
optimum parameters for a model built by machine learning is to see its performance 
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either by independent validation set or cross validation. In this work, models were 
validated by using both manually segregated a part of data as independent validation 
set, and also by cross validation. There are various types of cross validation 
commonly used in many statistical studies such as repeated random sub-sampling 
cross validation, k-fold cross validation, and leave one out cross validation. In this 
work, we have applied 5-fold cross validation. For 5-fold cross-validation, these 
compounds are randomly divided into five subsets of equal size. Each of these folds 
contains roughly equal number of samples (including positives and negatives), 
thereby rendering it a stratified cross-validation.  Four subsets are selected as the 
training set and the fifth as the validation set. This process is repeated five times such 
that every subset is selected as a validation set once. The SVM models were saved in 
each case and prediction were done for validation data (Figure 2-3). 
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Figure 2- 3 5 fold cross validation 
 
2.5.2 Performance evaluation methods  
The performance of SVM, k-NN, PNN and other machine learning methods can be 
derived from the numbers of true positives (TP), true negatives (TN), false positives 
(FP) and false negatives (FN) in a testing dataset166. The performance of 5-fold cross 
validation studies have been typically measured167 by the quantities of sensitivity 
=SE FNTP
TP
+  (prediction accuracy for positives), specificity =SP FPTN
TN
+  (prediction 
accuracy for negatives), overall prediction accuracy(Q) and Matthew’s correlation 
coefficient (C) 168. 
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                                                                        (10)                     
    (11) 
VS performance in screening large libraries has been typically measured169 by the 
quantities of yield = SE (percentage of known positives predicted as virtual hits), hit-
rate = TP/(TP+FP) (percentage of virtual hits that are known positives), false-hit rate 
= FP/(TP+FP) (percentage of virtual hits that are known negatives) and enrichment 
factor EF = hit rate / (TP+FN)/(TP+FN+TN+FP) (magnitude of hit-rate improvement 
over random selection).  
 
2.5.3 Overfitting  
Overfitting is major concern in machine learning classification method. There are two 
main types of overfitting: (1) using a model that is more flexible than it needs to be 
and (2) using a model that includes irrelevant descriptors. The reason for overfitting is 
usually linked with the model having high number of degrees of freedom compared to 
the number of records. Other possible reason for overfitting could be the 
conformability of the model in accordance to data shape, and the extent of model 
error matched up to the expected level of data error. Overfitting can be often observed 
when learning was performed too long or where training examples are rare or big 
differences were found in performance of cross validation and independent testing or 
at big database screening, analysis of selected hits show some based structure features. 
To avoid overfitting, it is necessary to use additional techniques (e.g. cross-validation, 






( ) ( ) ( ) ( ) FP TN FN TN FP TP FN TP 
FP FN TN TP  C 
+ + + + 
× − × = 
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comparison)170 that can indicate when further training is not resulting in better 
generalization. In this study,  cross-validation, independent testing171 and database scan 
are used.   
 
2.6 Machine learning classification based virtual screening platform 
2.6.1 Generation of putative negatives and building of SVM based 
virtual screening system 
As for prediction of compound inhibitors, positives can be formed from known active 
compounds but negatives are usually lacking. Previous studies have used known 
inactive compounds and active compounds of other biological target classes as 
putative inactive compounds 35, 72, 148-151, 172, 173.  In our group a new approach 
extensively used for generating inactive proteins in SVM classification of various 
functional classes of proteins 174-176 has been attempted for generating putative 
inactive compounds62.  
 
In a similar manner, known compounds can be grouped into compound families by 
clustering them in the chemical space defined by their molecular descriptors 177, 178. 
As SVM predict compound activities based on their molecular descriptors, in 
developing SVM VS tools, it makes sense to cluster as well as to represent 
compounds in terms of molecular descriptors. By using a K-means method 177, 178 and 
molecular descriptors computed from our own software 179, we generated 8,423 
compound families from the 13.56M compounds in the PUBCHEM and MDDR 
databases that we were able to compute the molecular descriptors, which is consistent 
with the 12,800 compound-occupying neurons (regions of topologically close 
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structures) for 26.4 million compounds of up to 11 atoms 180, and the 2,851 clusters 
for 171,045 natural products 181. 
 
The whole process of our SVM based VS system can be divided into five main steps. 
First compound inhibitors of a certain target were collected from papers. After 
processing by removal of salts and converted to 3D structures using Corina (Section 
2.3.1). They were calculated with descriptors (Section 2.3.1). Descriptors were further 
scaled according to the range of all PubChem compounds. Second, they were divided 
into a training set and an independent testing set. Because there are few negatives 
being reported in the literature, virtual negatives were generated using our putative 
negative generation method (Section 2.6.1). The putative negatives were generated by 
taking eight representative samples from each of the non-active families. In total 
around 60,000 putative negatives were generated and added to training dataset. Third, 
the software LibSVM158 was chosen to perform the machine learning(Section 2.4.1). 
SVM separates the positives from the negatives with a hyperplane by mapping the 
input vectors to a higher dimensional feature space using a kernel function. Radial 
Basis Function (RBF) kernel, a non-linear SVM method, is used due to its 
consistently better performance. Optimally, hard margin SVM was used with a 
gamma scan for best performance, as determined from the five-fold cross-validation 
results.  Fourth, a model was built with all training compounds at this gamma. The 
model was then tested using the independent testing set. Fifth and finally, MDDR and 
PubChem database were screened and screening results are analyzed or subjected to 
further processing. This is the general process for SVM based VS system.  
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2.6.2 Discussions SVM based virtual screening system 
An advantage of this approach is its independence on the knowledge of known 
inactive compounds and active compounds of other biological target classes, which 
enables more expanded coverage of the “inactive” chemical space in cases of limited 
knowledge of inactive compounds and compounds of other biological classes. A 
drawback of this approach is the possible inclusion of some yet-to-be-discovered 
active compounds in the “inactive” class, which may affect the capability of SVM for 
identifying novel active compounds. As has been demonstrated in an earlier study62, 
such an adverse effect is expected to be relatively small for many biological target 
classes. In applying this approach to proteins, all known proteins are clustered into 
~8,933 protein domain families in based on the clustering of their amino acid 
sequences 121, and a set of putative inactive proteins can be tentatively extracted from 
a few representative proteins in those families without a single known active protein. 
Undiscovered active proteins of a specific functional class typically cover no more 
than a few hundred families, which gives a maximum possible “wrong” family 
representation rate of <10.2% even when all of the undiscovered active proteins are 
misplaced into the inactive class 182. Importantly, inclusion of the representative of a 
“wrong” family into the inactive class does not preclude other active family members 
from being classified as active. Statistically, a substantial percentage of active 
members can be classified by ML methods as active even if its family representative 
is in the inactive class 182, 183. Therefore, in principle, a reasonably good SVM 
classification model can be derived from these putative inactive samples, which has 
been confirmed by a number of studies of proteins 174-176, 182. 
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The number of compound inhibitors of a specific target is usually around 1000 and 
distributed in several hundred families respectively.  Because of the extensive effort 
in searching the known compound libraries for identifying active compounds in these 
target classes, the number of undiscovered “active” families in PUBCHEM database 
is expected to be relatively small, most likely no more than several hundred families. 
The ratio of the discovered and undiscovered “active” families (hundreds) and the 
families that contain no known active compound (~8423 based on the current versions 
of PUBCHEM and MDDR) for these and possibly many other target classes is 
expected to be <15%. Therefore, putative inactive training datasets can be generated 
by extracting a few representative compounds of those families that contain no known 
active compound in the active training set, with a maximum possible “wrong” family 
representation rate of <15% even when all of the undiscovered active compounds are 
misplaced into the inactive class, and with the expectation that a substantial 
percentage of active members in the putative “inactive” families can be classified as 
active despite of their family representatives are placed into the inactive training sets. 
As has been shown in a recent study of SVM VS tools, a substantial percentage of 
identified virtual hits are from these “inactive” families183. 
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Chapter 3 Update of TTD and Development of IDAD 
3.1 Introduction to TTD and IDAD 
3.1.1 Introduction to TTD and current problems 
Pharmaceutical agents generally exert their therapeutic effects by binding to and 
subsequently modulating the activity of a particular protein, nucleic acid or other 
molecular (such as membrane) target184, 185. Target discovery efforts have led to the 
discovery of hundreds of successful targets (targeted by at least one approved drug) 
and >1,000 research targets (targeted by experimental drugs only)16-19. Rapid 
advances in genomic, proteomic, structural, functional and systems studies of the 
known targets and other disease proteins186-192 enable the discovery of drugs, multi-
target agents, combination therapies and new targets16, 19, 186, 193, 194, analysis of on-
target toxicity195 and pharmacogenetic responses196, and development of discovery 
tools197-200. To facilitate the access of information about therapeutic targets, publicly 
accessible databases such as Drugbank201, PDTD 202 and our own TTD203 have been 
developed (Figure 3-1). These databases complement each other to provide target and 
drug profiles but have different emphasis. DrugBank is an excellent source for 
comprehensive drug data with information about drug actions and multiple targets201. 
PDTD contains active-sites as well as functional information for potential targets with 
available 3D structures202. TTD provides information about the primary targets of 
approved and experimental drugs203.  
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Figure 3- 1 Customized search page of TTD 
 
TTD was first developed to provide information about therapeutic targets and 
corresponding drugs in 2002 by our group. To accommodate increasing demand for 
comprehensive knowledge about the primary targets of the approved, clinical trial and 
experimental drugs, numerous improvements and updates are needed. However, since 
the first built-up of the TTD database about 6 years ago, there had been no major 
update and the following problems are found to be addressed: 
1. There have been significant increase of data of targets and drugs and they have 
not been updated to the database. Originally the targets of drugs are only 
separated in approved targets and experimental targets.  They shall be more 
clearly defined as successful, clinical trial and research targets based on research 
stages of drugs; 
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2. The main targets of some drugs are not clearly defined. This is also the problem 
of Drugbank which shows several drug targets but there is no information about 
the primary target; 
3. There are no structures and activity data for the collected drugs. The original 
collected information is only drug name.  Related information about drug 
structures, activities and cross-linking to other database like PubChem, DrugBank 
are not added; 
4. There is no standardized target ID which makes it inconvenient to cite TTD; 
5. The target is designed based on targets and for each target page there are drugs 
related to that target. However, there is no drug information page which shows 
the drug mode of action which lists the targets of this drug; 
6. There are no similarity searching for targets and drugs; 
7. There is no convenient customized downloading. 
 
3.1.2 The objective of update TTD and building IDAD 
We hope to make the updated TTD to be a useful information portal by providing 
comprehensive information about the primary targets and other drug data for the 
approved, clinical trial, and experimental drugs. To achieve this, we need to greatly 
increase the information of targets and drugs. Moreover, to increase the convenience 
for using this database, more features shall be added. These include cross-linkings to 
other data sources, similarity search, customized download and etc.  
The initial idea of building a drug activity database is to provide activity information 
for the main targets of the drugs and clinical trials compounds in TTD. With the 
development of this database, we feel that the scope shall not be limited to drugs and 
clinical trials compounds. Compounds like natural product compounds, important 
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compounds developed by the pharmaceutical companies as lead compound or 
preclinical candidates shall be included too. On the market there are similar database 
that provides activity information for compounds like BindingDB204, 205, DrugBank201, 
206 and MDDR207 (Table 3-1). BindingDB is a public, web-accessible database of 
measured binding affinities, focusing chiefly on the interactions of protein considered 
to be drug-targets with small, drug-like molecules. DrugBank is a unique 
bioinformatics and cheminformatics resource that combines detailed drug (i.e. 
chemical, pharmacological and pharmaceutical) data with comprehensive drug target 
(i.e. sequence, structure, and pathway) information. MDDR is a database covering the 
patent literature, journals, meetings and congresses produced by Symyx and Prous 
Science. As compared to those databases, IDAD is mainly focusing in in vitro activity 
of drugs, clinical trial compounds and preclinical candidates while BindingDB 
collects data of all kinds of compounds binding to the targets, which are not limited to 
therapeutic targets. In IDAD, the compounds and activity are well organized 
according to targets while in DrugBank and MDDR, the activity data are not well 
organized according to targets.  
 
Table 3- 1 Main drug-binding databases available on-line 
No Database URL 
1 BRENDA http://www.brenda-enzymes.info/ 
2 DrugBank  http://www.drugbank.ca/ 
3 eMolecules  http://www.emolecules.com/ 
4 MDDR http://www.symyx.com/products/databases/bioactivity/m
ddr/index.jsp 
5 PNPDB  http://azevedolab.net/14.html 
6 PubChem  http://nihroadmap.nih.gov 
7 SCOWLP  http://www.scowlp.org/ 
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8 ShikiPDB  http://azevedolab.net/14.html 
9 SuperNatural  http://bioinformatics.charite.de/supernatural/ 
10 SuperHapten  http://bioinformatics.charite.de/superhapten/ 
11 WOMBAT http://www.sunsetmolecular.com 
12 ZINC  http://zinc.docking.org/ 
 
3.2 Update of TTD 
3.2.1 Update on target and validation of primary target 
After the update, 1,894 targets, 560 diseases and 5,028 drugs are located in the 
database. This is a significant increase of data as compared to the 433 targets, 125 
diseases, and 809 drugs in the original release described in previous paper. These 
targets have been further divided into 348 successful, 292 clinical trial and 1,254 
research targets.  
While drugs typically modulate the activities of multiple proteins208 and up to 14,000 
drug-targeted-proteins have been reported206, the reported number of primary targets 
directly related to the therapeutic actions of approved drugs is limited to only 32418. 
Information about the primary targets of more comprehensive sets of approved, 
clinical trial and experimental drugs is highly useful for facilitating focused 
investigations and discovery efforts against the most relevant and proven targets19, 186, 
193, 195, 196, 200. Therefore, we updated TTD by significantly expanding the target data to 
include 348 successful, 292 clinical trial, and 1,254 research targets, and added drug 
data for 1,514 approved, 1,212 clinical trial and 2,302 experimental drugs linked to 
their primary targets (3,382 small molecule and 649 antisense drugs with available 
structure and sequence, more structures will be added). 
Literature search was conducted by searching PubMed database using keyword 
combinations of “therapeutic” and “target”, “drug” and “target”, “clinical trial” and 
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“drug”, and “clinical trial” and “target”, and by comprehensive search of such review 
journals as Nature Reviews Drug Discovery, Trends of Pharmaceutical Science, Drug 
Discovery Today and etc. In particular, these searches identified 198 recent papers 
reporting approved and clinical trial drugs and their targets. As many of the 
experimental antisense drugs are described in US patents, we specifically searched US 
patent databases to identify 745 antisense drugs targeting 104 targets. Primary targets 
of 211 drugs and drug binding modes of 79 drugs are not specified in our collected 
documents. Further literature search was conducted to find the relevant information 
for these drugs. The criteria for identifying the primary target of a drug or targets of a 
multi-target drug is based on the developer or literature reported cell-based or in-vivo 
evidence that links the target to the therapeutic effect of the drug. These searched 
documents are listed in the respective target or drug entry page of TTD and crosslink 
is provided to the respective PubMed abstract, US patent, or developer web-page. 
We collected a slightly higher number of successful targets than the reported number 
of 320 targets18 because of the identification of protein subtypes as the targets of some 
approved drugs and the inclusion of multiple targets of approved multi-target drugs 
and non-protein/nucleic acid targets of anti-infectious drugs (e.g. bacterial cell wall 
and membrane components). Clinical trial drugs are based on reports since 2005 with 
the majority since 2008. Clinical trial phase is specified for every clinical trial drug.  
 
3.2.2 Chemistry information for the TTD database 
In addition to the targets, 5,028 drugs are further divided into 1,514 approved, 1,212 
clinical trial and 2,302 experimental drugs. Additional data about the approved, 
clinical trial and experimental drugs and their primary targets were collected from a 
comprehensive search of literatures, Drugs@FDA209 webpage, latest reports from 17 
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pharmaceutical companies that describe clinical trial and other pipeline drugs 
(Astrazeneca, Bayer, Boehringer Ingelheim, Genentech, GSK, Idenix, Incyte, ISIS, 
Merck, Novartis, Pfizer, Roche, Sanofi Aventis, Schering-Plough, Spectrum, Takeda, 
Teva).  Compounds with known structures in literatures are drawn using 
CambridgeSoft ChemDraw software210. Further structures were obtained from drug 
names queries in PubChem database. Structures in 2D format were further converted 
into 3D structures using Corina software211.  Jmol is used to display the 2D and 3D 
structures of the drugs212. Descriptors were calculated with MODEL software136 118. 
 
3.2.3 Target and drug data collection and access 
TTD data can be accessed by keyword or customized search. Customized search 
(Figure 3-2) fields include target name, drug name, disease indication, target 
biochemical class, target species, drug therapeutic class, and drug mode of action. 
Search results of target information page and drug information page are listed in 
Figure 3-2 and Figure 3-3. Further information about each target can be accessed via 
crosslink to UniProtKB Swiss-Prot213, PDB214, KEGG215, OMID, and Brenda216 
database. Further drug information can be accessed via crosslink to PubChem217, 
DrugBank218, SuperDrug219, and ChEBI220. Related target or drug entries can be 
recursively searched by clicking a disease or drug name. Similarity targets of an input 
protein sequence in FASTA format can be searched by using the BLAST sequence 
alignment tool221. Similarity drugs of an input drug structure can be searched by using 
molecular descriptor based Tanimoto similarity searching method163, 222. Target and 
drug entries are assigned standardized TTD IDs for easy identification, analysis and 
linkage to other related databases. The whole TTD data, target sequences along with 
Swiss-Prot and Entrez gene IDs, and drug structures can be downloaded via the 
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download link. A separate downloadable file contains the list of TTD drug ID, drug 
name and the corresponding IDs in other cross-matching databases PubChem217, 
DrugBank218, SuperDrug219, and ChEBI220. The corresponding HGNC name and 
Swiss-Prot and Entrez gene ID of each target is provided in the target page. The 
SMILES and InCHI of each drug is provided in the drug page. 
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Figure 3- 2 Target information page of TTD 
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Figure 3- 3 Drug information page of TTD 
 
3.2.4 Database function enhancements 
3.2.4.1. Target similarity searching 
Target similarity searching (Figure 3-4) is based on the BLAST221 algorithm to 
determine the similarity level between the sequence of an input protein and the 
sequence of each of the TTD target entries. The BLAST program was downloaded 
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from NCBI website223. The similarity targets are ranked by E-value and BLAST 
score221. E-value has been reported to give reliable predictions of the homologous 
relationships224 and E-value cutoff of 0.001 can be used to find 16% more structural 
relationships in the SCOP database than when using a standard sequence similarity 
with a 40% sequence-identity threshold225. The majority of protein pairs that share 
40–50% (or higher) sequence-identity differ by <1 Å RMS deviation226, 227, and a 
larger structural deviation probably alters drug-binding properties. An example of 
search result is listed in Figure 3-5. 
 
 
Figure 3- 4 Target similarity search page of TTD 
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Figure 3- 5 Target similarity search results of TTD 
 
3.2.4.2. Drug similarity searching 
Drug similarity searching (Figure 3-6) is based on the Tanimoto similarity searching 
method163. An input compound structure in MOL or SDF format is converted into a 
vector composed of molecular descriptors by using our MODEL software228. 
Molecular descriptors are quantitative representations of structural and 
physicochemical features of molecules, which have been extensively used in deriving 
structure-activity relationships, QSARs and VS tools for drug discovery118, 169. Based 
on the results of our earlier studies222, a total of 100 1D and 2D descriptors were used 
as the components of the compound vector. The vector of an input compound i is then 
compared to drug j in TTD by using the Tanimoto coefficient sim(i,j) 163 (Section 
2.4.4 in Chapter 2). Tanimoto coefficient of similarity compounds are typically in the 
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range of 0.8 to 0.9164, 165. Hence compound i is considered to be very similar, similar, 
moderately similar, or un-similar to drug j if  sim(i,j) > 0.9, 0.85< sim(i,j) <0.9, 0.75< 




Figure 3- 6 Drug similarity search page of TTD 
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Figure 3- 7 Target similarity search results of TTD 
 
3.3 The development of  IDAD database 
3.3.1 The data collection of related information 
Literature search was conducted by searching PubMed database using keyword 
combinations of “therapeutic” and “target”, “drug” and “target”, “clinical trial” and 
“drug”, and “clinical trial” and “target”, and by comprehensive search of such review 
journals as Journal of Medicinal Chemistry, European Journal of Medicinal 
Chemistry, Current Topics in Medicinal Chemistry, Nature Reviews Drug Discovery, 
Trends of Pharmaceutical Science, Drug Discovery Today, Oncogene and etc. In 
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particular, these searches identified 198 recent papers reporting approved and clinical 
trial drugs and their targets. 
 
3.3.2 The construction of IDAD database 
IDAD is a relational database, which represents the drug-target interaction database in 
the form of two-dimension tables. The two-dimensional tables include IDAD ID-Drug 
Name pair ID table, IDAD ID-Activity ID pair main information table, Activity ID, 
Protein ID, Activity,  Normalized  Activity, Reference ID table,  Protein ID – TTDID 
and Swiss-Prot ID information table and Reference information table. In these tables, 
IDAD serves as primary key; Activity ID, Protein ID, reference ID are considered as 
foreign keys. TTDID and Swiss-Prot ID are used to cross-link to external database 
like TTD and Swiss-Prot. 
 
3.3.3 The interface of the IDAD database 
The IDAD database can be found at the BIDD 
website http://bidd.nus.edu.sg/group/IDAD/IDAD_Home.asp. Entries of this database 
are searchable by several methods. These methods include the search by compound 
name or ID, search by target. Case-insensitive keyword-based text search and 
wildcards are also supported. In a query, one can specify full name or part of the name 
in a text field. For instance, wild characters of '*' and '?' are allowed in the text field. 
In this case, '?' represents any single character, and '*' represents a string of characters 
of any length. As an example, input of ‘hdac’ in the field of target name enables the 
search of all entries containing the target name of ‘hdac’ such as hdac1, hdac8, hdac4, 
etc. The outcome of a typical target search and compound search results are illustrated 
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in Figure 3-8 and Figure 3-9. In this interface, all entries that satisfy search criteria 
are listed along with IDAD ID, target name, activity, and reference.  More detailed 
information of a compound can be obtained by clicking the corresponding TTD 
targetID, TTD drugID. For a systematic comparison of compound activities, all 
activity values are normalized. For completeness, the relevant references are provided 
in the interface.  
 
Figure 3- 8 Information page of Drug Activity Database – target search result 
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Figure 3- 9 Information page of Drug Activity Database - compound search result 
 
3.4 Statistic analysis of therapeutic targets 
Based on the known information about the targets and drug activities, therapeutic 
targets were analyzed in terms of different properties. The biochemical class 
distribution for successful and clinical trial targets are very similar (Figure 3-10) but 
there are some differences in terms of distribution of  properties like molecular weight, 
numbers of hydrogen bond donors and acceptors, LogP,  potency (Figure 3-11). 
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Drugs show a slightly lower MW, LogP, number of H bond acceptor and potency than 
clinical trial compounds.  
 
 
Figure 3- 10 Biochemical class distributions for successful and clinical trial targets 
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Figure 3- 11 Distributions of approved and clinical trial drugs by MW, LogP, H-bond 
donor, H-bond acceptor and potency of approved and clinical trial drugs 
 
3.5 Conclusion 
The updated TTD is intended to be a more useful resource in complement to other 
related databases by providing comprehensive information about the primary targets 
and other drug data for the approved, clinical trial, and experimental drugs. In 
addition to the continuous update of new target and drug information, efforts will be 
devoted to the incorporation of more features into TTD. Increasing amounts of data 
about the genomic, proteomic, structural, functional and systems profiles of 
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therapeutic targets have been and are being generated186-192. Apart from establishing 
crosslink to the emerging data sources, some of the profiles extracted or derived from 
the relevant data16 may be further incorporated into TTD. Target data has been used 
for developing target discovery methods198-200, some of these methods may be 
included in TTD in addition to the BLAST tool for similarity target searching. As in 
the case of PDTD202, some of the VS methods and datasets118, 205 may also be 
included in TTD for facilitating target oriented drug discovery. IDAD is a drug 
activity database of drug and clinical trial compounds. The integration of those 
information lead to analysis of properties of drug and clinical trials compounds. It 
reveals some differences between them in terms of several properties. All these 
information and further analysis could lead to a better understanding of the reasons 
for failures of clinical trials in drug discovery. 
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Chapter 4 Virtual Screening of Abl Inhibitors from Large 
Compound Libraries  
4.1 Introduction 
Abl plays key roles in cancers by regulating morphogenesis and motility, and by 
promoting cell growth and survival via BCR-ABL (an oncogene fusion protein 
consisting of BCR and ABL genes) mediated activation of Src-family kinases and 
PI3K (Phosphatidylinositol 3-kinase) , Ras (a protein superfamily of small GTPases), 
Myc (a protein belongs to Myc family of transcription factors that binds to the DNA), 
c-jun (a protein that forms the AP-1 early response transcription factor), and STAT 
(Signal Transducer and Activator of Transcription protein) pathways229. Abl inhibitors 
are effective in the treatment of leukemia and in clinical trials of other cancers230-232. 
In some cases, these inhibitors show negligible activity against common mutations 
and modest effects in advanced cancer phases, and some patients develop resistance 
associated with Abl kinase domain mutations232. The successes and problems of these 
inhibitors have raised significant interest in and led to intensifying efforts for 
discovering new Abl inhibitors232, 233. Several in-silico methods have been used for 
facilitating the search and design of Abl inhibitors, which include pharmacophore234, 
QSAR235, scaffold assembly236, molecular docking237, 238, and their combinations239, 
240.  
 
These in silico methods have shown impressive capability in the identification of 
potential Abl inhibitors, but their applications may be affected by such problems as 
the vastness and sparse nature of chemical space that needs to be searched, 
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complexity and flexibility of target structures, difficulties in accurately estimating 
binding affinity and solvation effects, and limited diversity of training active 
compounds22, 241, 242. Therefore, it is desirable to explore other in silico methods that 
complement these methods by expanded coverage of chemical space, increased 
screening speed, and reduced false-hit rates without necessarily relying on the 
modeling of target structural flexibility, binding affinity and solvation effects.  
 
A LBVSmethod, SVM, has been explored as such a method that produces high 
yields and low false-hit rates in searching active agents of single and multiple 
mechanisms from large compound libraries (i.e. with an expanded applicability 
domain) 62 and in identifying active agents of diverse structures62, 148-151. Good VS 
performance can also be achieved by SVM trained from sparsely distributed active 
compounds62. SVM classifies active compounds based on differentiating 
physicochemical profiles between active and inactive compounds rather than 
structural similarity to active compounds per se, which has the advantage of not 
relying on the accurate computation of structural flexibility, binding affinity and 
solvation effects. Moreover, the fast speed and expanded applicability domain of 
SVM enables efficient search of vast chemical space. Therefore, SVM may be a 
potentially useful VS tool to complement other in silico methods for searching Abl  
inhibitors from large libraries. 
 
In this work, we developed a SVM VS model for identifying Abl inhibitors, and 
evaluated its performance by both 5-fold cross validation test and large compound 
database screening test. In the 5-fold cross validation test, a dataset of Abl inhibitors 
and non-inhibitors was randomly divided into 5 groups of approximately equal size, 
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with 4 groups used for training a SVM VS tool and 1 group used for testing it, and the 
test process is repeated for all 5 possible compositions to derive an average VS 
performance. In the large database screening test, a SVM VS tool was developed by 
using Abl inhibitors published before 2008, its yield (percent of known inhibitors 
identified as virtual-hits) was estimated by using Abl inhibitors reported since 2008 
and not included in the training datasets, virtual-hit rate and false-hit rate in searching 
large libraries were evaluated by using 13.56M PubChem, 168K MDDR, and 6,638 
MDDR compounds similar in structural and physicochemical properties to the known 
Abl inhibitors.  
 
PubChem and MDDR contain high percentages of inactive compounds significantly 
different from the Abl inhibitors, and the easily distinguishable features may make VS 
enrichments artificially good243. Nonetheless, certain percentages of PubChem and 
MDDR compounds are kinase inhibitors or are similar to known Abl inhibitors. For 
instance, about 1500 MDDR and 10,000 PubChem compounds are kinase inhibitors, 
and 6,638 MDDR compounds are similar to at least one known Abl inhibitor. 
Therefore, VS performance may be more strictly tested by using these and other 
compounds that resemble the physicochemical properties of the known Abl inhibitors 
so that enrichment is not simply a separation of trivial physicochemical features165. To 
further evaluate whether our SVM VS tool predict Abl inhibitors and non-inhibitors 
rather than membership of certain compound families, distribution of the predicted 
active and inactive compounds in the compound families were analyzed.  
 
Moreover, VS performance of SVM was compared to those of two similarity-based 
VS methods, Tanimoto similarity searching and kNN, and an alternative but equally 
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popularly used machine learning method, PNN method, based on the same training 
and testing datasets (same sets of PubChem and MDDR compounds) and molecular 
descriptors. In a study that compares the performance of SVM to 16 classification 
methods and 9 regression methods, it has been reported that SVMs shows mostly 
good performances both on classification and regression tasks, but other methods 
proved to be very competitive244. Therefore, it is useful to evaluate the VS 
performance of SVM in searching large compound libraries by comparison with those 
of both similarity-based approaches and other typical machine learning method. 
 
4.2 Materials 
A total of 708 Abl inhibitors, with IC50<50µM, were collected from the 
literatures239, 245-247 and the BindingDB database205. The inhibitor selection criterion of 
IC50<50µM was used because it covers most of the reported HTS and VS hits248, 249. 
The structures of representative Abl inhibitors are shown in Figure 4-1. A total of 100 
important descriptors were chosen from a total of 525 chemical descriptors calculated 
by our program MODEL which were used for generating Abl inhibitor prediction 
model. As few non-inhibitors have been reported, putative non-inhibitors were 
generated using our method for generating putative inactive compounds133, 222.  
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Figure 4- 1 Structures of representative Abl inhibitors 
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4.3 Results and discussion 
4.3.1 Performance of SVM identification of Abl inhibitors based on 5-
fold cross validation test 
The 5-fold cross validation test results of SVM in identifying Abl inhibitors and 
putative non-inhibitors are given in Table 4-1. The accuracies for predicting 
inhibitors and non-inhibitors are 84.4%~92.3% and 99.96%~99.99% respectively. 
The Q and C are 99.79%~99.90% and 0.808~0.915 respectively. The inhibitor 
accuracies of our SVM are comparable to or slightly better than the reported 
accuracies of 58.3%~67.3% for protein kinase C inhibitors by SVM-RBF and CKD 
methods250, 83% for leukocyte-specific protein tyrosine kinase (Lck) inhibitors by 
SVM method251, and 74%~87% for inhibitors of any of the 8 kinases (3 Ser/Thr and 5 
Tyr kinases) by SVM, ANN, GA/kNN, and RP methods252. The non-inhibitor 
accuracies are comparable to the value of 99.9% for Lck inhibitors251 and 
substantially better than the typical values of 77%~96% of other studies250, 252. 
Caution needs to be raised about straightforward comparison of these results, which 
might be misleading because the outcome of VS strongly depends on the datasets and 
molecular descriptors used.  Based on these rough comparisons, SVM appears to 
show good capability in identifying Abl inhibitors at low false-hit rates. Similar 
prediction accuracies were also found from two additional 5-fold cross validation 
studies conducted by using training-testing sets separately generated from different 
random number seed parameters. 
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Abl inhibitors Abl non-inhibitors 
Q (%) C Number of 
training/testing 
inhibitors 




TN FP SP (%) 
1 566/142 131 11 92.25 52395/13099 13098 1 99.99 99.91 0.915 
2 566/142 125 17 88.03 52395/13099 13094 5 99.96 99.83 0.845 
3 566/142 128 14 90.14 52395/13099 13097 2 99.98 99.88 0.886 
4 567/141 119 22 84.40 52395/13099 13094 5 99.96 99.80 0.808 
5 567/141 128 13 90.78 52396/13098 13093 5 99.96 99.86 0.872 
Average    89.12    99.97 99.86 0.865 
SD    0.0304    0.000149 0.000434 0.0407 
SE    0.0136    0.00007 0.00019 0.0182 
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4.3.2 Virtual screening performance of SVM in searching Abl 
inhibitors from large compound libraries  
SVM VS tool for searching Abl inhibitors from large libraries were developed by 
using Abl kinases reported before 2008 as described in the methods section. The VS 
performance of SVM in identifying Abl inhibitors reported since 2008 and in 
searching MDDR and PubChem databases is summarized in Table 4-2. The yield in 
searching Abl inhibitors reported since 2008 is 50.5%, which is comparable to the 
reported 50%~94% yields of various VS tools253. Strictly speaking, direct comparison 
of the reported performances of these VS tools is inappropriate because of the 
differences in the type, composition and diversity of compounds screened, and in the 
molecular descriptors, VS tools and their parameters used. A more appropriate 
comparison based on the same training and testing datasets and molecular descriptors 
were conducted, which are described in a following section. 
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Table 4- 2 Virtual screening performance of SVMs for identifying Abl inhibitors from large compound libraries 
Method Inhibitors in Training 
Set 



































































70.3% 26(56.5%) NA 6,638 (3.95%) 6,638 (100%) 
KNN 58.2% 10(21.7%) 79,043 (0.58%) 1,662 (0.99%) 550(8.3%) 
PNN 58.2% 10(21.7%) 83,293 (0.61%) 1,686 (1.00%) 546(8.2%) 
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Virtual-hit rates and false-hit rates of SVM in screening compounds that resemble the 
structural and physicochemical properties of the known Abl inhibitors were evaluated 
by using 6,638 MDDR compounds similar to an Abl inhibitor in the training dataset. 
Similarity was defined by Tanimoto similarity coefficient ≥0.9 between a MDDR 
compound and its closest inhibitor62. SVM identified 330 virtual-hits from these 6,638 
MDDR similarity compounds (virtual-hit rate 4.97%), which suggests that SVM has 
some level of capability in distinguishing Abl inhibitors from non-inhibitor similarity 
compounds. Significantly lower virtual-hit rates and thus false-hit rates were found in 
screening large libraries of 168K MDDR and 13.56M PubChem compounds. The 
numbers of virtual-hits and virtual-hit rates in screening 168K MDDR compounds are 
659 and 0.39% respectively. The numbers of virtual-hits and virtual-hit rates in 
screening 13.56M PubChem compounds are 29,072 and 0.21% respectively.  
 
The collected Abl inhibitors are distributed in 221 families. Because of the 
extensive efforts in searching kinase inhibitors from known compound libraries, the 
number of undiscovered Abl inhibitor families in PubChem and MDDR databases is 
expected to be relatively small, most likely no more than several hundred families. 
The ratio of the discovered and undiscovered inhibitor families (hundreds) and the 
families that contain no known inhibitor of each kinase (8,423 based on the current 
versions of PubChem and MDDR) is expected to be <15%. Therefore, putative non-
inhibitor training dataset can be generated by extracting a few representative 
compounds from each of those families that contain no known inhibitor, with a 
maximum possible “wrong” classification rate of <15% even when all of the 
undiscovered inhibitors are misplaced into the non-inhibitor class. The noise level 
generated by up to 15% “wrong” negative family representation is expected to be 
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substantially smaller than the maximum 50% false-negative noise level tolerated by 
SVM149. Based on earlier studies133, 222 and this work, it is expected that a substantial 
percentage of the un-discovered inhibitors in the putative “non-inhibitor” families can 
be classified as inhibitor despite their family representatives are placed into the non-
inhibitor training sets.  
 
It is noted that, in the database screening test, 50.0% of families that contain Abl 
inhibitors reported since 2008 are not covered by the Abl inhibitor training dataset 
(inhibitors reported before 2008), and the representative compounds of these families 
were deliberately placed into the inactive training sets as these inhibitors are not 
supposed to be known in our study. As shown in earlier studies133, 222 and in this work, 
a substantial percentage of the inhibitors in these misplaced inhibitor-containing “non-
inhibitor” families were predicted as inhibitors by our SVM VS tool. Moreover, a 
small percentage of the compounds in these putative non-inhibitor datasets are 
expected to be un-reported and un-discovered inhibitors, their presence in these 
datasets is not expected to significantly affect the estimated false hit rate of SVM.  
 
Substantial percentages of the MDDR virtual-hits belong to the classes of 
antineoplastic, signal transduction inhibitors, tyrosine-specific protein kinase 
inhibitors, antiarthritic and antiangiogenic (Table 4-3, details in next section). As 
some of these virtual-hits may be true Abl inhibitors, the false-hit rate of our SVM is 
at most equal to and likely less than the virtual-hit rate. Hence the false-hit rate is 
<3.95% in screening 6,638 MDDR similarity compounds, <0.39% in screening 168K 
MDDR compounds, and <0.21% in screening 13.56M PubChem compounds, which 
are comparable and in some cases better than the reported false-hit rates of 
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0.0054%~8.3% of SVM133, 222, 0.08%~3% of structure-based methods, 0.1%~5% by 
other machine learning methods, 0.16%~8.2% by clustering methods, and 1.15%~26% 
by pharmacophore models253.  
 
To facilitate the selection of true Abl inhibitors from the SVM identified virtual-hits, 
one may explore a consensus approach that selects potentially promising virtual-hits 
based on the consensus scores of multiple VS methods that include molecular docking, 
similarity methods, and pharmacophore models as well as SVM253. Our preliminary 
study showed that 20% of the 659 SVM virtual-hits from MDDR database were 
selected by molecular docking, which include 128 compounds that belong to the 
tyrosine-specific protein kinase inhibitor class. This suggests that a consensus 
approach is potentially useful for enriching true-hit selection rates. 
 
4.3.3 Evaluation of SVM identified MDDR virtual-hits 
SVM identified MDDR virtual-hits were evaluated based on the known biological 
or therapeutic target classes specified in MDDR. Table 4-3 gives the MDDR classes 
that contain higher percentage (>=6%) of SVM virtual-hits and the percentage values. 
We found that 310 or 47% of the 659 virtual-hits belong to the antineoplastic class, 
which represent 1.4% of the 21,557 MDDR compounds in the class. In particular, 105 
or 16% of the virtual-hits belong to the tyrosine-specific protein kinase inhibitor class, 
which represent 8.9% of the 1,181 MDDR compounds in the class. Moreover, 18% 
and 6% of the virtual-hits belong to the signal transduction inhibitor and 
antiangiogenic classes, representing 5.7% and 2.5% of the 2,037 and 1,629 members 
in the two classes respectively. Therefore, many of the SVM virtual-hits are 
antineoplastic compounds that inhibit tyrosine kinases and possibly other kinases 
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involved in signal transduction, angiogenesis and other cancer-related pathways. 
While some of these kinase inhibitors might be true Abl inhibitors, the majority of 
them are expected to arise from false selection of inhibitors of other kinases.  
 
Table 4- 3 MDDR classes that contain higher percentage (≥6%) of virtual-hits 
identified by SVMs in screening 168K MDDR compounds for Abl inhibitors 
Kinase Number of 
SVM Identified 
Virtual Hits 
MDDR Classes that 
Contain Higher 






Percentage of Class 
Members Selected 
as Virtual Hits 







Antiarthritic 98 0.9% 
Antiangiogenic 40 2.5% 
 
A total of 98 SVM virtual-hits belong to the antiarthritic class. An Abl inhibitor 
Gleevec has been reported to be effective in treatment of arthritis, which is probably 
due to its inhibition of other related kinases such as c-kit and PDGFR254. Moreover, 
several other kinases have been implicated in arthritis. EGFR-like receptor stimulates 
synovial cells and its elevated activities may be involved in the pathogenesis of 
rheumatoid arthritis255. VEGF has been related to such autoimmune diseases as 
systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis256. FGFR 
may partly mediates osteoarthritis257. PDGF-like factors stimulates the proliferative 
and invasive phenotype of rheumatoid arthritis synovial connective tissue cells258. Lck 
inhibition leads to immunosuppression and has been explored for the treatment of 
rheumatoid arthritis and asthma259. Therefore, some of the SVM virtual-hits in the 
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antiarthritic class may be inhibitors of these kinases or their kinase-likes capable of 
producing antiarthritic activities.  
 
4.3.4 Comparison of virtual screening performance of SVM with 
those of other virtual screening methods 
To evaluate the level of performance of SVM and whether the performance is due 
to the SVM classification models or to the molecular descriptors used, SVM results 
were compared with those of three other VS methods based on the same molecular 
descriptors, training dataset of Abl inhibitors reported before 2008, and the testing 
dataset of Abl inhibitors reported since 2008, 168K MDDR and 13.56M PubChem 
compounds. The three other VS methods include two similarity-based methods, 
Tanimoto-based similarity searching and kNN methods, and an alternative machine 
learning method PNN.  As shown in Table 4-2, the yield and maximum possible 
false-hit rate of the Tanimoto-based similarity searching, kNN and PNN methods are 
70.33% and 3.95%, 58.24% and 0.99%, and 58.24 and 1% respectively. Compared to 
these results, the yield of SVM is smaller than but still comparable to these similarity-
based VS method, and the false-hit rate of SVM is significantly reduced by 10.1, 2.5, 
and 2.6 fold respectively. These suggests that SVM performance is due primarily to 
the SVM classification models rather than the molecular descriptors used, and SVM is 
capable of achieving comparable yield at substantially reduced false-hit rate as 
compared to both similarity-based approach and alternative machine learning method. 
Our results are consistent with the report that SVM shows mostly good performances 
both on classification and regression tasks, but other classification and regression 
methods proved to be very competitive244. 
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4.3.5 Does SVM select Abl inhibitors or membership of compound 
families? 
To further evaluate whether our SVM VS tools identify Abl inhibitors rather than 
membership of certain compound families, Compound family distribution of the 
identified Abl inhibitors and non-inhibitors were analyzed. A total of 19.6% of the 
identified inhibitors belong to the families that contain no known Abl inhibitors. For 
those families that contain at least one known Abl inhibitor, >70% of the compounds 
(>90% in majority cases) in each of these families were predicted as non-inhibitor by 
SVM. These results suggest that our SVM VS tool identify Abl inhibitors rather than 
membership to certain compound families. Some of the identified inhibitors not in the 
family of known inhibitors may serve as potential “novel” Abl inhibitors. Therefore, 
as in the case shown by earlier studies 62, SVM has certain capacity for identifying 
novel active compounds from sparse as well as regular-sized active datasets. 
 
4.4 Conclusion 
SVM shows substantial capability in identifying Abl inhibitors at comparable yield 
and in many cases substantially lower false-hit rate than those of typical VS tools 
reported in the literatures and evaluated in this work. It is capable of searching large 
compound libraries at sizes comparable to the 13.56M PubChem and 168K MDDR 
compounds at low false-hit rates without the need to define an applicability domain, 
i.e. it has a broad applicability domain that covers the whole chemical space defined 
by the current versions of PubChem and MDDR databases. The performance of SVM 
is substantially improved against several other VS methods based on the same 
datasets and molecular descriptors, suggesting that the VS performance of SVM is 
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primarily due to SVM classification models rather than the molecular descriptors used. 
Because of their high computing speed and generalization capability for covering 
highly diverse spectrum compounds, SVM can be potentially explored to develop 
useful VS tools to complement other VS methods or to be used as part of integrated 
VS tools in facilitating the discovery of Abl inhibitors and other active compounds260-
262.  
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Chapter 5 Identifying Novel Type ZBGs and Non-
hydroxamate HDAC Inhibitors through a SVM Based 
Virtual Screening Approach 
5.1 Introduction 
Histone deacetylase inhibitors (HDACi) produce anti-cancer effects by regulating 
excessive histone acetylation and inducing apoptosis, and their successes have been 
demonstrated by several drugs approved (e.g. SAHA) and in clinical trials (e.g. 
Avugane, Romidepsin)263. Appearance of high numbers of incidences of reduced 
efficacies and resistance to HDACi treatments have led to intensive efforts for 
developing new HDACi264. Known HDACi typically consist of a zinc-binding group 
(ZBG) and a cap connected by a linker 265, 266 (Figure 5-1), with ZBGs primarily 
derived from hydroxamic acid derivatives (e.g. SAHA)267 and non-hydroxamates (e.g. 
small fatty acids, o-aminoanilides, electrophilic ketones, N-formyl hydroxylamines, 
thiols and mercaptoamides)265. Table 5-1 shows examples of HDACi and their ZBGs 
together with reported potency ranges and problems. Some hydroxamate HDACi tend 
to show poor pharmacokinetics268, severe toxicity269, and low specificity towards 
HDAC isozymes270. Some non-hydroxamate HDACi are metabolically labile (e.g. 
1,3-diketone), strongly reactive (e.g. epoxide), low in potency (e.g. o-aminoanilide, 
carboxylic acid), and prone to side effects (e.g. thiol)265. Hence, there is a strong need 
for searching new HDACi free of these problems from more diverse chemical 
libraries263,264.  
 Chapter 5 Prediction of Novel Type ZBGs and Non-hydroxamate HDAC Inhibitors 
 81 
 
Figure 5- 1 Structural characteristics of HDAC inhibitor SAHA265, 266. 
 
 Chapter 5 Prediction of Novel Type ZBGs and Non-hydroxamate HDAC Inhibitors 
 82 
Table 5- 1 Examples of known HDACi and related compounds, associated ZBGs, observed potencies in inhibiting HDAC, and reported 
problems 
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Efforts have been directed at expanded search of the chemical space, rational 
modification of linker and cap groups, and the introduction of pro-drugs263,264. 
Some of these efforts have been facilitated by the use of such virtual VS tools as 
ligand-based  QSAR271-275, 3D-QSAR276-281, and pharmacophore282, and 
structure-based molecular docking 283-288. The applicability domains of these 
ligand-based methods in some cases are restricted289, 290 by limited diversity 
(<200 compounds in most cases) 291-293 or structural types (e.g. hydroxamic acid 
derivatives only) in training dataset. Application of these structure-based 
methods may be affected by the complexity and flexibility of target structures 
and difficulties in accurately estimating binding affinity and solvation effects22, 
241. Therefore, it is desirable to explore other VS methods to complement these 
VS tools for expanded coverage of chemical space. 
 
In this work, we explored a machine learning method SVM, and used a 
significantly expanded training dataset to develop an HDACi VS tool capable of 
screening large libraries at good yield and low false-hit rate. SVM was used 
because of its good VS performance in searching active agents of single and 
multiple mechanisms from large libraries62 based on training datasets of sparsely 
distributed active compounds62, and in identifying agents of diverse activities 
and structures62, 148-151. SVM classifies active compounds based on 
differentiating physicochemical profiles between active and inactive compounds 
rather than structural similarity to active compounds per se, which has the 
advantage of not requiring the knowledge of target structure and the need to 
compute activity-related features, binding affinity and solvation effects. A 
significantly more diverse training dataset was generated by extensive literature 
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search of reported HDACi and generation of structurally diverse putative non-
HDACi by using our published method that requires no knowledge of inactive 
compounds or active compounds of other target classes133, 222. 
 
Two types of SVM VS tools were developed. One is the all HDACi SVM 
(AH-SVM) developed by using all known hydroxamate and non-hydroxamate 
HDACi. The second is the hydroxamate HDACi SVM (HH-SVM) developed by 
using hydroxamate HDACi only. This SVM is designed to test the method for 
predictability of novel type ZBGs and HDAC inhibitors. VS performance of both 
types of SVM VS tools was evaluated by two testing methods. The first method 
is 5-fold cross validation in which a dataset was randomly divided into 5 groups 
of approximately equal size, with 4 groups used for training and 1 group used for 
testing the VS model, and the testing process was conducted for all 5 possible 
training-testing dataset compositions. The second method is independent 
evaluation such that a VS tool was developed by using HDACi published before 
2008, with its performance estimated by using HDACi reported since 2008 and 
by using 13.56M PubChem, 168K MDDR (including 202 HDACi). PubChem 
and MDDR contain high percentages of inactive compounds significantly 
different from the HDACi, and the easily distinguishable features may make VS 
enrichments artificially good243. Therefore, VS performance is more strictly 
tested by using subset of MDDR compounds similar to the dual-inhibitors so that 
enrichment is not simply a separation of trivial physicochemical features165.  
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5.2 Materials 
We collected from literatures published in 1991-2009 a total of 1730 HDAC 
compounds. Based on HDAC activity, they are further classified as inhibitors (1,488 
HDACi with IC50≤20µM), weak inhibitors (84 weak HDACi with 
20µM<IC50≤200µM) and Unknown compounds (158 compounds with activity value 
like IC50>10µM which are unclassified and will not be used for this study.). The 
HDACi selection criterion of IC50≤20µM for inhibitors was used because it covers 
most of the reported HTS and VS hits248, 249. The weak HDACi selection criterion of 
20µM<IC50≤200µM was based on the consideration that the largest reported IC50 
values of inhibitors are typically in the range of 50~100µM248, 249). All HDACi are 
distributed in 702 compound families (method for deriving compound families 
described in our earlier publication133, 222 and their structural diversity index is 0.506, 
which is comparable to that of the structurally diverse estrogen receptor agonist 
dataset167. Therefore, our collected HDACi are fairly diverse in structures and 
physicochemical properties, and they are significantly higher in numbers than the 
40~200 compounds used in developing ligand-based HDACi prediction tools reported 
in the literatures (QSAR271-275, 3D-QSAR276-281, and pharmacophore282).  
 
Among the 1488 HDACi and 84 weak HDACi, there are 1,268 HDACi, 70 weak 
HDACi published before 2008, and 220 HDACi, 14 weak HDACi published since 
2008. In order to validate our studies, two validation tests were used. The first one is 
5-fold cross validation studies in which the whole set of 1,488 HDACi were 
separately used for training and testing VS tools. The second one is independent 
evaluation studies in which the 1,268 pre-2008 HDACi were separately used for 
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training VS tools and model is then tested by 220 HDACi and 70 weak HDACi 
reported since 2008 and further validated by using the 202 HDACi from MDDR 
database which could be found in supplement information 2. Overall, 36.4% of the 
220 HDACi published since 2008 and 53.5% of the 202 MDDR HDACi are 
distributed in the compound families covered by the HDACi in the training dataset. 
Hence, our testing datasets have substantial degree of novelty for testing the VS 
performance of SVM. Most of the currently known HDACi are hydroxamate 
HDACi. One of current research focuses is to design non-hydroxamate HDACi. 
Therefore, we conducted another study to build the HH-SVM model on hydroxamate 
HDACi using similar approaches.   
 
A total of 100 important descriptors were chosen from a total of 525 chemical 
descriptors calculated by our program MODEL which were used for generating 
HDAC inhibitor prediction model. Because few non-HDACi have been reported in 
the literature, putative non-HDACi were generated by using our method that requires 
no knowledge of inactive compounds or active compounds of other target classes and 
enables more expanded coverage of the “non-inhibitor” chemical space133, 222. A total 
of 62,198 compounds extracted from the 7853 families that contain no known HDACi 
were used as the putative non-HDACi.  
 
5.3 Results and discussions 
5.3.1 5-fold cross validation test  
The 5-fold cross validation results of AH-SVM and HH-SVM are given in 
Table 5-2. The best gamma was found at 204 for both models. The average 
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accuracies for AH-SVM prediction of HDACi and non-HDACi are 86.83% and 
99.75%, and the Q and C are 99.45% and 0.772 respectively. The average 
accuracies for HH-SVM prediction of hydroxamate HDACi and non-HDACi are 
86.61% and 99.92%, and the Q and C for hydroxamate HDACi prediction are 
99.77% and 0.796 respectively. Both AH-SVM and HH-SVM showed reasonably 
good performance in predicting HDACi and hydroxamate HDACi, and very high 
accuracy rate in predicting non-HDACi. The HDACi prediction accuracies of 
AH-SVM are comparable to the reported 88% accuracy for predicting 100 
HDACi by a pharmacophore model282. The non-inhibitor accuracies are 
substantially better than the reported 91.8% accuracy of the pharmacophore 
model282 and the typical values of 77%~96% of other studies250, 252.  
 
Table 5- 2 Performance of SVMs for identifying all types or hydroxamate type 
HDAC inhibitors and non-inhibitors evaluated by 5-fold cross validation study.  
Inhibitor 
Type 
Parameter SE (%) SP (%) Q (%) C 
All types sigma=204 86.83 99.75 99.45 0.772 
Hydroxamate 
type 
sigma=204 86.61 99.92 99.77 0.796 
 
While it is highly desirable to assess the performance of SVM by comparison 
with those of other VS models based on the same training and testing datasets, 
this is not yet fully possible because of the reported HDACi VS models are 
primarily QSAR and pharmacophore models trained by dozens or less HDACi 
that are significantly less than the >100 compounds typically needed for 
developing a good SVM VS model62. For instance, a pharmacophore model 
developed by multiple classes of ZBG, which is the most appropriate for 
comparison with multi-class-based SVM model, has been developed based on the 
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features of 20 strong, medium and weak HDACi282. A SVM model developed by 
using the same training dataset of 20 HDACi, which is not expected to be a 
sufficiently good VS model, nonetheless identified 47.9% of the HDACi in the 
same testing dataset as compared to the reported 91.8% HDACi identification 
rate282.  
 
Caution needs to be raised about straightforward comparison of these results, 
which might be misleading because the outcome of VS strongly depends on the 
datasets and molecular descriptors used.  Based on these rough comparisons, 
SVM appears to show good capability in identifying HDACi at low false-hit 
rates. Similar prediction accuracies were also found from two additional 5-fold 
cross validation studies conducted by using training-testing sets separately 
generated from different random number seed parameters. 
 
5.3.2 Virtual screening performance in searching HDAC inhibitors 
from large compound libraries  
The AH-SVM and HH-SVM developed by pre-2008 HDACi were used for 
identifying HDACi reported since 2008 and for searching MDDR and PubChem 
databases, and the results are summarized in Table 5-3. The yields of the AH-
SVM in searching 220 HDACi reported since 2008 and 202 MDDR HDACi are 
44.1% and 46.0%, which are slightly lower than the reported 50%~94% yields of 
various VS tools294. The yield of the HH-SVM in searching 101 hydroxamate 
HDACi and 99 MDDR hydroxamate HDACi are 51.5% and 57.6%. If HH-SVM 
is used to scan 220 HDACi reported since 2008 and 202 MDDR HDACi, the 
yields are 24.5% and 32.2%. The 220 HDACi in our testing dataset can be 
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divided into 80 and 140 HDACi covered and un-covered by the compound 
families in SVM training dataset respectively, 71.3% and 28.6% of which were 
correctly identified by AH-SVM (Table 5-3). For HH-SVM, the results are 
91.7% and 46.1%. SVM shows certain level of capacity in identifying novel 
HDACi.  
 
Strictly speaking, direct comparison of the reported performances of these VS 
tools is inappropriate because of the differences in the type, composition and 
diversity of compounds screened, and in the molecular descriptors, VS tools and 
their parameters used. The comparison cannot go beyond the statistics of 
accuracies and is only intended as a rough estimate of the VS performance of our 
SVM VS tools. AH-SVM also identified 71.4% of the 14 weak HDACi.  HH-
SVM identified 76.9% of the 13 weak hydroxamate HDACi respectively. These 
suggest that our developed SVM has some capacity in recognizing weak HDACi 
that share similar structural and physicochemical features with HDACi. The 
recognition of substantial percentages of possible HDACi as HDACi likely arises 
from the possibility that some of these possible HDACi are at least weak HDACi. 
 
Table 5- 3 Virtual screening performance of SVMs developed by using all HDAC 
inhibitors (all HDACi SVM) and by using hydroxamate HDAC inhibitors 
(hydroxamate HDACi SVM) for identifying HDAC inhibitors from large 
compound libraries. Inhibitors, weak inhibitors are HDAC inhibitors with 
reported IC50≤20µM, 20µM<IC50≤200µM in the literatures respectively. 
MDDR inhibitors are HDAC inhibitors in the MDDR database. 




Number of Inhibitors 1,268 702 
Number of Chemical 
Families Covered by 
570 325 




Testing Set  
Number of Inhibitors  / 
MDDR inhibitors / Weak 
Inhibitors  
220/202/14  101/99/13 
Number of Chemical 
Families Covered by 
Inhibitors / MDDR inhibitors  
/ Weak Inhibitors 
89/141/9 47/76/8 
Number of Inhibitors  / 
MDDR inhibitors / Weak 
Inhibitors in train chemical 
families 
80/108/3 12/59/3 
Percent of Inhibitors / MDDR 
inhibitors  / Weak Inhibitors 





Hit number of Inhibitors   / 
MDDR inhibitors  /  Weak 
Inhibitors  
97/93/10 52/57/10 
Yield for Inhibitors   / MDDR 
inhibitors  /  Weak Inhibitors  
44.1%/46.0%/71.4% 51.5%/57.6%/76.9% 
Number of Identified  True 
Inhibitors  / MDDR inhibitors  
/  Weak Inhibitors  Inside 
Training Chemical Families 
57/85/2 11/53/3 
Percent of Identified  True 
Inhibitors  / MDDR inhibitors  
/ Weak Inhibitors  Inside 
Training Chemical Families 
71.3%/78.7%/66.7% 91.7%/89.8%/100.0% 
 
Number of Identified  True 
Inhibitors  / MDDR inhibitors  
/  Weak Inhibitors  Outside 
Training Chemical Families 
40/8/8 41/4/7 
Percent of Identified  True 
Inhibitors  / MDDR inhibitors  
/ Weak Inhibitors  Outside 
Training Chemical Families 
28.6%/8.5%/72.7% 46.1%/10.0%/70.0% 
Number and Percent of 
13.56M PubChem 
Compounds Identified as 
Inhibitors 
74,664(0.55%) 15,065(0.11%) 
Number and Percent of the 
168K MDDR Compounds 
Identified as Inhibitors 
1,723(1.03%) 492(0.293%) 
Number of MDDR 
Compounds Similar to 
Known HDAC Inhibitors 
(Tanimoto Similarity > 0.9)  
14,712 9,366 
Number and Percent of 
Similar Compounds 
Predicted as Inhibitors. 
607(4.1%) 205(2.2%) 
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Virtual-hit rates of AH-SVM and HH-SVM in screening compounds that 
resemble the structural and physicochemical properties of the known HDACi and 
hydroxamate HDACi were evaluated by using  14,712 and 9,366 MDDR 
compounds similar to the known HDACi and hydroxamate HDACi in the 
training dataset. Similarity was defined by Tanimoto similarity coefficient ≥0.9
between a MDDR compound and its closest inhibitor62. AH-SVM and HH-SVM 
identified 607 and 205 virtual-hits from the 14,712 and 9,366 MDDR similarity 
compounds (virtual-hit rate 4.1% and 2.2%) respectively, which suggests that 
SVM has some level of capability in distinguishing HDACi from non-inhibitor 
similarity compounds. Significantly lower virtual-hit rates and thus false-hit 
rates were found in screening large libraries of 168K MDDR and 13.56M 
PubChem compounds. The numbers of virtual-hits in AH-SVM and HH-SVM 
screening of 168K MDDR compounds are 1,723 and 492, and the corresponding 
and virtual-hit rates are 1.03% and 0.29%, respectively. The numbers of virtual-
hits in AH-SVM and HH-SVM screening of 13.56M PubChem compounds are 
74,664 and 15,065, and the corresponding virtual-hit rates are 0.55% and 0.11% 
respectively.  
 
The identified MDDR virtual-hits primarily belong to the MDDR classes of 
antineoplastic (which contains 93 HDACi), antiarthritic, 
antiallergic/antiasthmatic, antihypertensive, collagenase inhibitor, thrombin 
inhibitor, neutral endopeptidase inhibitor, gpIIb/IIIa receptor antagonist, matrix 
metalloproteinase inhibitor, neuronal injury inhibitor, adrenoceptor (beta3) 
agonist, endothelin antagonist, farnesyl protein transferase inhibitor, ACE 
inhibitor, lipoxygenase inhibitor, and factor Xa inhibitor (Table 5-4, details in 
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next section). As some of these virtual-hits may be true HDACi, the false-hit rate 
of our SVM is at most equal to and likely less than the virtual-hit rate. Hence the 
false-hit rates of AH-SVM and HH-SVM are <4.1% and <2.2% in screening 
6,638 MDDR similarity compounds, <1.03% and <0.29% in screening 168K 
MDDR compounds, and <0.55% and <0.11% in screening 13.56M PubChem 
compounds, which are comparable and in some cases substantially better than 
the reported false-hit rates of 0.0054%~8.3% of SVM133, 222, 0.08%~3% of 
structure-based methods, 0.1%~5% by other machine learning methods, 
0.16%~8.2% by clustering methods, and 1.15%~26% by pharmacophore 
models294. 
Table 5- 4 MDDR classes that contain >1% of virtual-hits identified by SVMs in 
screening 168K MDDR compounds for HDAC inhibitors 
MDDR Classes that Contain >1% of Virtual 
Hits  
No (Percentage) of 
Virtual Hits in Class 
Percentage of Class 
Members Selected 
as Virtual Hits 
Antineoplastic (including 93 HDACi) 331 (19.2%) 2.06% 
Antiarthritic 305 (17.7%) 3.52% 
Antiallergic/Antiasthmatic 133 (7.7%) 1.39% 
Antihypertensive 131 (7.6%) 1.25% 
Collagenase Inhibitor 107 (6.2%) 19.56% 
Thrombin Inhibitor 57 (3.3%) 4.64% 
Neutral Endopeptidase Inhibitor 52 (3.0%) 8.09% 
gpIIb/IIIa Receptor Antagonist 44 (2.6%) 3.27% 
Matrix Metalloproteinase Inhibitor 44 (2.6%) 5.99% 
Neuronal Injury Inhibitor 43 (2.5%) 0.92% 
Adrenoceptor (beta3) Agonist 39 (2.3%) 6.98% 
Endothelin Antagonist 39 (2.3%) 4.79% 
Farnesyl Protein Transferase Inhibitor 30 (1.7%) 2.33% 
ACE Inhibitor 29 (1.7%) 5.17% 
Lipoxygenase Inhibitor 29 (1.7%) 1.08% 
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Factor Xa Inhibitor 26 (1.5%)  1.93% 
Tryptase Inhibitor 20 (1.2%) 10.47% 
 
 
5.3.3 Evaluation of SVM identified MDDR virtual-hits 
The SVM virtual hits are yet to be validated by experiments to determine the 
capability of SVM in identification of new HDACi and novel HDAC zinc 
binding motifs. Nonetheless, some indications of this capability may be partially 
probed by examining the features of SVM virtual hits in comparison with known 
HDACi and other relevant therapeutic agents. The MDDR virtual-hits identified 
by AH-SVM were evaluated based on the known biological or therapeutic target 
classes specified in MDDR. Table 5-4 gives the MDDR classes that contain >1% 
of the AH-SVM virtual-hits and the percentage of the class members identified 
as virtual hits. We found that 331 or 19.2% of the 1,723 virtual-hits belong to the 
antineoplastic class, which represent 2.1% of the 21,557 MDDR compounds in 
the class. In particular, 93 or 28% of these virtual-hits are known HDACi found 
in MDDR. A total of 305 (17.7%) and 133 (7.7%), of the AH-SVM virtual-hits 
belong to the antiarthritic and antiallergic/antiasthmatic classes respectively. 
FK228, a HDACi, reportedly suppresses autoantibody-mediated arthritis in mice 
via regulation of p16INK4a and p21 (WAF1/Cip1) expression295. Other HDACi 
such as Trichostatin A exhibit inhibitory effects on rheumatoid arthritis synovial 
fibroblast proliferation296. HDACs regulate asthma and allergic diseases by 
altering the expression of distinct subsets of inflammatory/immune genes297 and 
some HDACi such as Trichostatin A has been found to attenuate airway 
inflammation in mouse asthma model298. Therefore, some of the AH-SVM 
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virtual-hits in the antiarthritic and antiallergic/antiasthmatic classes may possibly 
be true HDACi capable of producing the related therapeutic effects. Moreover, 
107 (6.2%) and 44 (2.6%) of the AH-SVM virtual-hits belong to the collagenase 
and matrix metalloproteinase inhibitor classes respectively.  Collagenase and 
Matrix Metalloproteinase are same class of zinc-dependent peptidases proteins 
like HDAC. ZBGs like hydroxamic acid, thiol group, epoxide and etc. have 
strong binding to Zinc group which makes them good inhibitors for zinc-
dependent peptidases. 
 
5.3.4 Evaluation of the predicted zinc binding groups of SVM virtual 
hits 
To investigate the structural class of the SVM virtual hits, substructure analysis 
was conducted. The structures of known HDACi belong to 9 classes as shown in 
Table 5-5. Analysis of HH-SVM virtual hits showed a good coverage of most 
types of known non-hydroxamate ZBGs except thoil, mercaptoketone and 
heterocyclic ketone (Table 5-5). This shows our method has a great potential of 
identifying new types of ZBGs.  
Table 5- 5 Zinc binding group classes of SVM virtual hits 
No Type Substructure AH-SVM HH-SVM 
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 Summary  15573 6700 
 Total  74,664 15,065 
 
Furthermore, substructure analysis shows several types of ZBGs, as listed in 
Figure 5-2, were identified from AH-SVM screening results. Some ZBGs are 
confirmed in recent publications of HDACi or found in inhibitors of other types 
of Zinc containing proteins such as Matrix Metalloproteinases. There are 7 major 
types of ZBGs. Type A (sulfonamides) are well known groups for carbonic 
anhydrase inhibitors. Potent sulfonamiade type HDACi have recently been 
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reported by MethylGene Inc 116, 299. Type B includes a series of cyano containing 
groups. Type C contains isothiocyanate and analogs. One analog, phenylhexyl 
isothiocyanate, has recently been reported to be a dual HDACi and 
hypomethylating agent and inhibit myeloma cell growth by targeting critical 
pathways300. Type D consists of a series of hydroxypyrones, hydroxypyridinones 
and hydroxypyrothione, many of which have been found in matrix 
metalloproteinases and anthrax lethal factor inhibitors301-303.  Two such 
compounds, phenol osajin and bi-phenol pomiferin, have recently been reported 
as weak HDACi with IC50 value of 6.53 µM and 1.05 µM respectively304. Type 
E is heterocyclic ketones. Type F includes a nitro group which has been found to 
serve as ZBGs in carboxypeptidase A inhibitors305. Type G is composed of a 
series of five member ring hetero cyclic compounds, some of which (e.g. 
barbiturates (G4), rhodanines (G5), thiadiazoles (G7) and hydantoin (G8)) act as 
ZBGs of MMP and TACE inhibitors301, 306-308.   
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Figure 5- 2 Examples of potential zinc binding groups and hit numbers from AH-
SVM PubChem screening hits. 
 
5.3.5 Evaluation of the predicted tetra-peptide cap of SVM virtual 
hits 
Another approach in designing HDACi is to derive potent inhibitors based on 
weak ZBGs. By optimization of linker and cap group, it is possible to convert 
compounds with a weak ZBG into nM range potent HDACi. This will take more 
time for the medicinal chemists. However, this approach is worth exploring 
because most strong ZBG are usually reactive electrophiles easily leading to 
toxicity while weak ZBGs usually do not have such problems. This approach has 
been explored by Merck to develop sulfonamides based HDACi299,309. If the cap 
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and linker group is good enough, it is still possible to derive a nM range potent 
HDACi with a weak ZBG like ketone, carbonyl acid and amide. Carboxylic acid 
is generally considered to be a very weak ZBG and not used for design of 
HDACi310-312. Out of the 44 collected carbonyl acid compounds, only 11 are 
HDACi and most of which bears a large tail group and have a MW over 500. Our 
SVM virtual hits include a number of carboxylic acid compounds, suggesting the 
possible existence of potentially interesting HDACi with weak ZBG like 
carboxylic acid.  
Tetra-peptide is the most well-known cap group. Well-known HDACi such as 
FK-225497, FR235222, trapoxin A and B, apicidin, chamydcon all have tetra-
peptide caps 313. There are also reports of pseudo-peptide caps like spirucostatin, 
YM753, FK-228313. Some types of caps are described as follows based on the 
ring size. R12 type tetrapeptides consist of four α amino acids. Most of the 
reported tetra-peptide structures like FK-225497, FR235222, trapoxin A and B, 
apicidin, chamydcon and HC toxin belong to this class. However, HC-toxin has a 
slight different type structure as to the connection position from tetra-peptide to 
ZBG (Figure 5-3). As to pseudo-peptide analogs, R12c (structure 4314) is a 
apicidin analog with 1,5-triazole ring to replace  the amid bond and  R12d  
(structure 2314) is an apicidin analog with 1,4-triazole ring to replace  the amid 
bond. Those reported structures are also active. Moreover, there are non-peptide 
analogs like (R12e CID:4394) and R12f (CID:16220721) in the screening hits. 
R13 type tetrapeptide cap is formed by replacing one of the α-amino acid in R12 
type tetra-peptide. There are four possible positions for replacement. The 
replacement gives structure α3β1 type tetra-peptide structures. Four kinds of 
replacement of α amino acids all give active structures310. Among them, 
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replacement at amino acid 1 gives azumamide A.  In SVM virtual hits, there are 
one series of peptide analogs like R13a (CID:10226946) in Figure 5-3 similar to 
azumamide A by replacing one amide bond to ester. Thus these compounds may 
be potential HDACi. However, none of this type of SVM virtual hits has an 
obvious ZBG. Other types of interested hits with a 13 member ring are R13b 
(CID:478379) and R13c (CID:10112548). R14 type tetra-peptide structure can be 
formed by replacement of two α amino acids into β amino acids. The 
replacement gives structure a2b2 type tetra-peptide structures. There are two 
types structures reported with replacements at amino acids 3 4 and  2 3310.  They 
have weak activity. Other types are unclear. In the screening hits, there are 
several types of multi peptide analogs like R14a (CID:10165223), R14b 
(CID:10255473) shown in Figure 5-3. R15 type penta-peptide structure can be 
formed by five α-amino acids, there is no reported known penta-peptide 
structures as HDACi. In screening hits there is one class like R15a (CID: 
3623355). However, the linker seems to be a bit too short. Moreover, there are 
some types of pseudo-peptide analogs like R15b, R15c, R15d, R15e and R15f as 
shown in Figure 5-3.  R15b (CID:10167312) is an acetylated reduced disulfide 
compound which bears with a 15 member ring. It will be further explained in 
R16 type structures.  R15c (CID: 9825993) is a type of simple non-peptide ring.  
R15d (CID:11848348), R15e (CID:11849153), R15f (CID:11849152) and R15g 
(CID:16660023) belong to a series of fused ring systems. Most of current known 
di-sulfide type peptide like structure belongs to R16 class and with a unique type 
of substructure. Romidepsin (FK228/depsipeptide) is the most famous di-sulfide 
natural product HDACi which has one α-amino acid in the tetra-peptide replaced 
with a beta-hydroxy acid.  Spiruchostatin A and B also belong to this class with 
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one amino acid replaced by statine. Largazole315 can be regarded as an analog of 
reduced FK228 which replace the two amide bonds with two five member rings. 
YM753316 has a 15 member ring which can be treated as an analog of reduced 
spiruchostatin A with the statine replaced by a beta-hydroxy acid. In SVM 
virtual hits, a type of structures like R15b (CID: 10167312) can be considered as 
acetyled form of the reduced YM753 and shall be active. Structural search of 
disulphide found that another type of R16 disulphide compound like R15h 
(CID:14759316) are also of potential interest. Moreover, there are pseudo-
peptide analogs like R16a (CID:16105256) and R16b (CID:10121104). 
Explorations of smaller sized ring like R9, R10 and R11 do not produce 
interesting hits. As to acyclic caps, derivatives containing the key LAoda 
aliphatic side chain in apicidin have been proved as good cap groups for design 
of none tetra-peptide HDACi317. Similar structures like CID:10073606, 
CID:10476346, CID: 11567826, CID:11569749, CID:11582665 in Figure 5-4 
were found from the SVM virtual hits which may serve as possible good caps 
alternative to LAoda. 
















































































































































































































































































Figure 5- 4 Examples of non cyclic caps alternative to LAoda in PubChem screening 
hits. 
 
5.3.6 Does SVM select HDAC inhibitors based on compound families 
or substructure? 
To further evaluate whether SVM identify HDACi rather than membership of 
certain compound families, Compound family distribution of the identified 
HDACi were analyzed. As shown in Section 3.2, study shows that SVM models 
can identify chemicals from outside the train chemical families but certainly 
have a better recover rate for testing compounds inside the train chemical 
families than those outside the train chemical families (Table 5-3). For AH-SVM, 
the results are 71.3% and 28.6%. For HH-SVM, the results are 91.7% and 46.1%. 
For those families that contain at least one known HDACi, >70% of the 
compounds (>90% in majority cases) in each of these families were predicted as 
non-HDACi by AH-SVM and HH-SVM. These results suggest that SVM identify 
HDACi rather than membership to certain compound families and substructure 
classes. 
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5.4 Conclusions 
SVM combined with our putative non-inhibitor generation method shows good 
performance in identification of HDAC inhibitors in both 5-fold cross validation and 
VS tests against independent datasets and large databases. Compared with other VS 
methods, SVM is capable of achieving comparable yields at very low false-hit rates 
similar to HTS in searching HDAC inhibitors from large compound libraries. SVM 
selects HDACi based on molecular descriptors rather than compound families or 
substructures and thus has a great potential of identifying novel type non-
hydroxamate structures. Those SVM virtual hits are yet to be experimentally validated 
to determine the capability of SVM in identification of new HDACi and novel HDAC 
zinc binding motifs. Nonetheless, analysis of the features of SVM virtual hits in 
comparison with known HDACi and other relevant therapeutic agents indicated the 
likelihood of such capability. In particular, SVM appears to be capable of recognizing 
special structural features of ZBGs and identify potential novel ZBGs found in known 
inhibitors of other zinc containing enzymes. This method can help medicinal chemists 
to quickly explore the diverse types of directions for development novel classes of 
inhibitors. Through this study, a series of novel ZBGs and cap groups are proposed 
which can guide medicinal chemists for design of novel type non-hydroxamate 
HDAC inhibitors with less PK and toxicity issues. 
 
Chapter 6 Development of a SVM Based Acute Toxicity Classification System 
 
Chapter 6 Development of a SVM Based Acute Toxicity 
Classification System Based On in vivo LD50 data 
6.1 Introduction 
Toxicology is the study of adverse effects of chemicals on living organisms, 
particularly humans. It has traditionally been evaluated by the dosing of animals to 
define well-established cytologic, physiologic, metabolic, and morphologic end-points. 
Acute toxicity is one of the widely conducted toxicology studies. It describes the 
adverse effects of a substance which result either from a single exposure318 or from 
multiple exposures in a short period of time (usually less than 24 hours)319. Acute 
toxicity is typically measured by LD50 which denotes dose that kills 50% of animals 
within 24 hours after administration. The information generated from acute toxicity 
studies is used in hazard identification and risk management in the context of 
production, handling, and use for various chemicals including environmental 
chemicals (IUR chemicals, pesticide actives and inerts, HPV chemicals, 
antimicrobials, water contaminants), pharmaceutical agents, agrochemicals, and 
consumer products and etc. Evaluation of acute toxicity is one of the big challenges 
faced by pharmaceutical companies and many administrative organizations including 
US Food and Drug Administration, European Union member countries, the 
organization for economic cooperation and development and the regulated 
communities because acute toxicity study is widely needed but is very costly, in terms 
of time, labor, compound synthesis and the sacrifice of large number of animals. 
Taking these concerns into consideration, the legislations in various countries have 
called for the use of information from alternative (non-animal) approaches like in 
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vitro methods, toxicogenomics methods or any in silico approaches, as a means of 
identifying the presence or absence of potential toxicity issues of the substances.  
 
The nature of acute toxicity is very complicated. There are multi types of toxic 
mechanisms including different model of actions of narcosis (I, II or III), oxidative 
phosphorylation uncoupling, respiratory inhibition, electrophilic/proelectrophilic 
reactivity, acetylcholinesterase (AChE) inhibition, or central nervous system (CNS) 
seizure mechanisms and etc.  Acute toxicity is always connected to ADME. It could 
be affected by many factors, for instance, local and/or target-organ specific effects, 
bioavailability of the compound (absorption, tissue distribution and elimination) and 
its metabolism (both bioactivation and detoxification). Chemically reactive 
metabolites generated from the bioactivation can modify tissue macromolecules, alter 
protein function which in turn may affect cell signalling, regulation, defence, function 
and viability.  They are the leading sources for hepatic toxicity, blood dyscrasias and 
hypersensitivity and other organ-directed toxicity. 
 
Prediction of acute toxicity initially started from the analysis of toxic substructures or 
toxicophores.  Some of the harshest reactivity effects are identified and removed 
using pre-defined alert substructures, e.g., acid halides, to remove undesirable 
compounds from consideration prior to their synthesis or acquisition. Analysis of 
toxicity database revealed many alert substructures. These predefined alert 
substructure filters which sometimes are called ‘garbage filters’ are used to remove 
compounds at compound acquisition or pre-screening in drug discovery320, 321. 
However, the problem is that many of such alert substructures are ‘chameleonic’ in 
nature, i.e., they may not necessarily cause toxic effects depending on other functional 
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groups and overall molecular structure (e.g., alkyl halides). Moreover, some 
‘chameleonic’ substructures are close related to the biological activity of the 
compound. To fix this, all ‘chameleonic’ substructures must be supplemented with 
class-specific QSARs, yielding toxicological expert systems80, 322. 
 
QSAR remains the primary approach for prediction of acute toxicities. Historically, 
toxicological predictions started with deriving simple log P correlations80, 322, 323. 
Further development of this idea is the hypothesis of Lipnick that this non-linear 
relationship (parabolic or bi-linear) describes the baseline toxicity (narcosis 
mechanism)324. Baseline QSAR (B-QSAR), Statistical QSAR (Stat-QSAR) and 
Fragmental QSARs (F-QSAR) represent three major types of QSAR approaches. 
Baseline QSAR (B-QSAR) implies the analysis of outliers from the baseline narcotic 
toxicity; Statistical QSAR (Stat-QSAR) approaches81, 325-327 use automated selection 
of the “best” descriptors that fit all data points into a single correlation; F-QSAR uses 
a sum of fragmental and interaction increments approach96, 328. All of these 
approaches are logically interrelated, but lead to quite different results. The use of 
QSAR in ecotoxicology is well established. There is a predominance of non-specific 
effects and log P is a sufficient predictor of the toxicity. Predictions can be made with 
sufficient accuracy for a number of endpoints and a large variety of chemicals. 
However, the situation in mammalian toxicology is different. In the field of 
mammalian toxicity the QSAR models are strictly limited to a well class of chemicals. 
Considering that the diverse types of structure in chemical database and multiple 
toxicity mechanisms involved, it is needed to combine specific chemical knowledge 
(rule-bases) with various types of predictive QSARs82-87, 89, 91, 92, 329 to develop various 
expert systems. Table 1-4 in chapter 1 lists the available commercial software for 
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predicting various toxicological endpoints. HazardExpert89 and DEREK91 are expert 
systems based on sub-structural fragments. TOPKAT81 is a collection of class-specific 
QSARs based on abstract descriptors. MCASE82-88 is a complex system that seems to 
be a collection of class-specific QSARs determined by automated fragmental analysis 
of deviations from baseline log P correlations. ToxScope90 and MDL Carcinogenicity 
Prediction93 are "data mining" systems that allow simple searching for information on 
chemically similar molecules. ADME/Tox is expert systems based on c-SAR from 
Pharma Algorithms Inc software80.  
  
On the use of QSARs in regulatory and other decision-making frameworks330, the 
predictive model should be associated with the following principles:  
(1) be associated with a defined endpoint that it serves to predict; 
(2) take the form of an unambiguous and easily applicable algorithm for predicting a 
pharmacotoxic endpoint; 
(3) have a clear mechanistic basis; 
(4) be accompanied by a definition of the domain of its applicability; 
(5) be associated with a measure of its goodness of fit and internal goodness of 
prediction estimated with cross validation or a method similar to a training set of data; 
(6) be assessed in terms of its predictive power by using data sets that were not used 
in the development of the model. 
 
Since any single QSAR equation must be related to the particular health effect322, in 
the expert systems, the entire data set must be split into sub-sets according to various 
health-effects, and separate QSAR equations must be derived for each effect. 
However, the knowledge of these effects is usually lacking and simple classification 
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based on compound types like amines, alcohols certainly can not meet the need. An 
iterative classification-QSAR(C-SAR) analysis becomes of the utmost importance 
which cannot be replaced with iterative descriptor selection which ignores the 
unknown health effects. The correct interpretation of statistical results is the most 
difficult part in deriving any predictive algorithm. Those interpretations certainly need 
the help from human expertise.  It is one of the major differences in different software 
on how to form the classes and determine the class-specificity of each equation. In 
TOPKAT, the classification is based on Compound Class. In Lipnick’s study, it is 
based on Outlier-based324 approaches and in AB/Tox, it is based on C-SAR approach. 
Figure 6-1 summarizes the existing methods of analysis for LC50 and LD50 values in 
a single logical scheme80. The top part of this scheme (paths a-b) refers to statistical 
QSARs that lead to “statistical induction” algorithms. These imply little or no 
differentiation of biological mechanisms, so they can only be used for compounds that 
are “homologous” to the training set. The bottom part of this scheme (paths c-h) refers 
to the combination of C-SAR, F-QSAR and “expert knowledge” methods. These are 
the major approaches in analyzing large data sets of mammalian LD50 values.  
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Figure 6-1 From SAR analysis to prediction (adopted from Zmuidinavicius, D. and 
etc80 ). 
 
Because there are usually large variations in measured LD50 data331, chemicals are 
usually classified by a simpler classification system. At present there are several 
chemical labeling and classification of acute systemic toxicity based on oral LD50 
values recommended by the Organization for Economic Co-operation and 
Development (OECD), WHO, US Environmental Protection Agency (EPA), 
European Union (EU) system and Globally Harmonized System (GHS)332.  Table 6-1 
lists current chemical classification systems based on oral rat LD50. Although there 
are differences between these systems, they generally agree that a chemical will be 
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classified as highly toxic if LD50 is less than 50 and not acutely toxic if LD50 is 
larger than 2000. Therefore in this study, the criterion is defined at 2000mg/kg b.w.  
 
Table 6-1 Current chemical classification systems based on rat oral LD50 (mg/kg 
b.w.) 
Class WHO OECD GHS U.S. EPA EU 
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For a predictive software, a good performance with specificity (percentage of true 
negatives predicted as negative) >=85% and sensitivity (percentage of true positives 
predicted as positives) >=85%  and false positives (true negatives predicted positive) 
<15% has been sought73.  For predictions of carcinogenicity74, 75, genetic toxicity76, 
reproductive and developmental toxicity77, and MRDD78, 79this has been achieved. 
However, for acute toxicity, it remains still a challenge. There are only a few reports 
regarding the performance of acute toxicity prediction modules from commercial 
software. Table 6-2 lists several studies on the performance of different approaches 
for prediction acute toxicity.  TOPKAT has been most often used for prediction of 
acute toxicity. As to QSAR regression, the Danish EPA evaluation of this model 
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using 1840 chemicals not contained in TOPKAT database gave very poor results 
(R2=0.31)333. As to classification, Boik JC334 developed a rat oral LD50 QSAR model 
constructed using Kernel Multitask Latent Analysis (KMLA) to screen promising 
anticancer compounds exhibit low systemic toxicity. The specificity and sensitivity 
are around 70%. Tunkel et al. did a comparison of several commercial QSAR models 
on regulatory purposes for 73 chemicals330 in which TOPKAT and MCASE show 67% 
to 70% accuracy. In a summary, current in silico approaches for acute toxicity, in 
terms of methods, model validation, prediction accuracy, are not satisfactory.  
Table 6-2 Studies on the performance of different approaches for prediction acute 
toxicity 





Dataset Results Ref. 
1 in silico 
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Why acute toxicity is so difficult to predict? Based on previous studies, several 
reasons may be derived.  
1. Mammalian toxicity measurements usually reflect whole body phenomena. They 
include process of absorption, distribution, bioaccumulation, metabolism and 
excretion. The compounds that lead to toxicities could be the active metabolites as 
well as the original compound. The toxicity could be caused by diverse types of 
toxicity mechanism or modes of toxic actions. The complexity and multiplicity of 
the mechanisms involved lead to inherent difficulties in the modeling process and 
trouble in developing single QSAR models for structural diverse substances.   
2. LD50 is the basis for the toxicological classification of chemicals. However, it is 
not always the best indication of acute toxicity. Converting the complex effect 
into a simple number LD50 certainly leads to a loss of information.  It does not 
take into account the dosage needed for achieving a therapeutic effect. It also does 
not take into account the toxic effects that do not result in death but are 
nonetheless serious (e.g. brain damage). Although convenient for regulatory 
classification proposes, LD50 has some shortcomings when used for modeling. It 
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is a challenge for QSAR based prediction of LD50 because we do not know which 
QSAR equation shall be applied. 
3. The quality of the biological data is another obstacle in the modeling process. The 
mammalian studies are often designed very loosely in relation to species, strains, 
sexes, exposure duration, means of administration, dose levels, etc. In a 1979 
report, LD50 values were observed to vary by as much as 3- to 11-fold between 
different laboratories331. 
4. The relative small number of substances for modeling. Although there is a big 
collection of LD50 data reported, for instance, RTECS339 database 
characterizes >100,000 unique compounds with ~1 million LD50 values, the 
actual LD50 value for specific specie and administration route is limited, for 
instance, there are only around 13k rat oral LD50 data. As compared with the total 
chemistry space, this is too small.   
5. The current classification systems were built on rat or mouse oral LD50 data. 
There are still big differences between rat and human.  
6. Most software adopted a QSAR based approach and any single QSAR equation 
must be related to the particular health effect and have a domain of applicability80. 
In QSAR based predictive toxicology, the entire data set must be split into sub-
sets according to various health effects, and separate QSAR equations must be 
derived for each effect.  Moreover, the training compounds for each QSAR define 
a specific domain of applicability for that equation. Only when the new 
compounds fall in the range of applicability domain of this equation and cause 
same biological effects reflected by this equations, the expert system can have a 
good prediction of the LD50 of this compound. 
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7. QSAR approaches (except C-SAR) usually used only very limited descriptors for 
modeling. It is hard to say how much these limited descriptors can model the 
complicated process and mechanism involved in the acute toxicity.   
To address the problems faced by QSAR based approaches, in this study SVM is 
explored as a new approach for prediction of acute toxicity to complement the 
existing approaches and to possibly extend the prediction range not yet covered by 
existing approaches. The following lists the reasons for choosing SVM: 
1. SVM is a powerful classification tool. It can classify active compounds based on 
the differentiating physicochemical profiles between active and inactive 
compounds other than structural similarity to active compounds.  
2. SVM can handle large and diverse dataset while QSAR can only handle small and 
co-generic dataset.  This is good for acute toxicity study which includes multi-
mechanisms of toxicity. It will be easier to build a single SVM model rather than 
relying on multi-QSAR equations.  
3. SVM is based on the structural risk minimization principle of statistical learning 
theory144, 145, which consistently shows outstanding classification performance, is 
less penalized by sample redundancy and can tolerate certain degree of error data. 
This is important for LD50 data which generally has large variations. 
4. SVM can use multi-descriptors to build the model but avoid over-fitting 
problem146, 147. For QSAR based approaches, only a few descriptors shall be 
finally selected to build the QSAR equation. It is needed to do descriptor selection 
using methods like genetic algorithm or PCA methods. SVM can use unlimited 
number of descriptors. The partial overlap in the descriptors is not expected to be 
a serious problem for SVM classification because SVM is less penalized by 
descriptor redundancy146, 147. 
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5. The definition of applicable domain is complicated for QSAR based expert system 
while for SVM there is not a big problem as long as the hyperplane which 
separates the positives and negatives could be correctly defined by the training 
dataset.  
6. LD50 data without a specific value can also be used for SVM based classification 
but not in QSAR based approaches. 
 
6.2 Materials 
6.2.1 Collection of acute toxicity compounds 
ChemIDplus340 is a free, web-based search system that provides access to structure 
and nomenclature authority files used for the identification of chemical substances 
cited in National Library of Medicine (NLM) databases including the TOXNET341 
system. TOXNET is a cluster of databases covering toxicology, hazardous chemicals, 
environmental health and related areas. TOXNET contains the most complete data 
records of acute toxicity and it provides free access to and easy searching of a list of 
dataset lists collected from databases or web links (Table 6-3),which includes well 
known database like RTECS339，HSDB342 and Drugs@FDA343. 
 
Table 6-3 Database lists in ChemIDplus system 
Class List Acronym  List Description 
File Locator CCRIS NCI Chem Carcino Res Info Sys 
File Locator ClinicalTrials.gov NIH ClinicalTrials.gov 
File Locator DailyMed NLM/FDA Drug Labelling 
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File Locator DART Developmental and Reprod.Tox. 
File Locator DrugPortal NLM Drug Information Portal 
File Locator EINECS EU Inv of Exist. Comm. Chem Sub 
File Locator EMIC Env. Mutagen Info. Center 
File Locator Haz-Map Occ. Exposure to Haz. Agents 
File Locator Household Products Household Products Database 
File Locator HSDB Hazardous Substances Data Bank 
File Locator MedlinePlusAll Search Consumer Health Info 
File Locator MeSH Medical Subject Headings File 
File Locator MeSH Heading Medical Subject Headings 
File Locator PubChem PubChem 
File Locator PubMed Biomedical Citations From PubMed 
File Locator PubMed AIDS AIDS Citations from PubMed 
File Locator PubMed Cancer Cancer Citations from PubMed 
File Locator PubMed Toxicology Toxicology Citations From PubMed 
File Locator RTECS Reg. of Toxic Eff. of Chem. Sub. 
File Locator TOXLINE NLM TOXLINE on TOXNET 
File Locator TOXMAP NLM Enviro. Health e-Maps 
Internet Locator CAMEO NOAA CAMEO Chemicals 
Internet Locator ChEBI Chem Entities of Biological Interest 
Internet Locator CTD Comparative Toxicogenomics Database 
Internet Locator Drugs@FDA FDA Drug Database 
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Internet Locator EPA Envirofacts EPA Master Chemical Integrator 
Internet Locator EPA HPVIS EPA High Prod Vol Info System 
Internet Locator EPA PPIS EPA Pest. Prod. Info. System 
Internet Locator EPA SRS EPA Substance Registry System 
Internet Locator IUCLID EU IUCLID Chemical Data Sheet 
Internet Locator NIOSH ICSC NIOSH Intl. Chem. Safety Cards 
Internet Locator NIOSH Pocket Guide NIOSH Pocket Guide to Chem Haz 
Internet Locator NIST WebBook NIST Chemistry WebBook 
Internet Locator NJ-HSFS New Jersey Haz. Sub. Fact Sheets 
Internet Locator NTP DBS NTP Database Search 
Internet Locator OSHA Chem OSHA Chemical Sampling Info 
Internet Locator SRC CHEMFATE Syracuse Res. Corp. CHEMFATE 
Internet Locator SRC DATALOG Syracuse Res. Corp. DATALOG 
Internet Locator USA.gov USA.gov Search Engine 
Superlist Locator CA65  
California List of Chemicals Known to 
Cause Cancer or Reproductive 
Effects 
Superlist Locator CAA1  Hazardous Air Pollutants 
Superlist Locator CAA2  Ozone Depletion Chemicals List 
Superlist Locator CGB  DOT Coast Guard Bulk Hazardous Materials 
Superlist Locator CGN  DOT Coast Guard Noxious Liquid Substances 
Superlist Locator DEA  Drug Enforcement Administration Controlled Substances 
Superlist Locator DOT  DOT Hazardous Materials Table 
Superlist Locator DSL  Domestic Substances List of Canada 
 Chapter 6 Development of a SVM Based Acute Toxicity Classification System 
 120 
Superlist Locator EINECS European Inventory of Existing Commercial Chemical Substances 
Superlist Locator FIFR EPA Pesticide List 
Superlist Locator GRAS Direct Food Substances Generally Recognized as Safe 
Superlist Locator HPV EPA High Production Volume Chemical List 
Superlist Locator IARC  International Agency of Research on Cancer List 
Superlist Locator INER List of Pesticide Product Inert Ingredients 
Superlist Locator MA  Massachusetts Substances List 
Superlist Locator MI  Critical Materials Register of the State of Michigan 
Superlist Locator MPOL  Marine Pollutants List 
Superlist Locator MTL  EPA Master Testing List 
Superlist Locator NJ  New Jersey Hazardous Substances List 
Superlist Locator NJEH New Jersey Extraordinarily Hazardous Substances List 
Superlist Locator NTPA NTP Carcinogens List 
Superlist Locator NTPT  NTP Technical Reports List 
Superlist Locator PA  Pennsylvania Right to Know List 
Superlist Locator PAFA List of Substances Added to Food in the U.S. 
Superlist Locator PEL OSHA Toxic and Hazardous Substances 
Superlist Locator PELS  The 1989 OSHA Toxic and Hazardous Substances List 
Superlist Locator REL  NIOSH Recommended Exposure Limits 
Superlist Locator RQ  CERCLA Hazardous Substances Table 302.4 
Superlist Locator S110 Superfund Amendments and Reauthorization Act of 1986 
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Superlist Locator S302 
Section 302 of the Superfund 
Amendments and Reauthorization 
Act of 1986 (SARA), Extremely 
Hazardous Substances 
Superlist Locator TLV  ACGIH Threshold Limit Value 
Superlist Locator TRI  Toxic Chemical Release Inventory 
Superlist Locator TSCAINV Toxic Substances Control Act Chemical Substances Inventory 
Superlist Locator WHMI Ingredient Disclosure List of Canada 
 
In TOXNET database there are together 110k toxicity records with 13548 rat oral 
LD50 data, 6205 rat intraperitoneal (ip) LD50 data, 3425 rat intravenous (iv) LD50, 
2506 rat subcutaneous (sub) LD50 data, 28000 mouse oral LD50  data, 42232 mouse 
ip LD50 data, 21319 mouse iv LD50 data, 8506 mouse  sub LD50 data. Actually, 
most of the collected data come from RTECS339, for instance, among the all rat oral 
LD50 13548 records, 13299 belong to RTECS339. 
 
6.2.2 Pre-processing of dataset 
Current datasets of acute toxicity are very complicated.  To support a ligand based 
computational studies, clean-up work need to be done for the compound.  In the 
Danish EPA study, it was limited to cover only ‘discrete organics’ meaning that 
UVCBs (Unknown, Variable Composition and Biologicals) and other ill-defined 
structures were excluded for practical reasons333. Inorganics substances were likewise 
not been evaluated because these are usually better approached by simpler methods of 
evaluating the availability of the respective an- and cations with well known hazard 
profiles. Organicmetallics compounds have also been excluded as being poor 
candidates for modeling. In this study we will also follow these rules too. Moreover, 
compound with error structures, polymers and compounds are removed. After that, 
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compounds were converted into 3D structures using CORINA135 and descriptors were 
calculated with our MODLE136, 118 software. Only compounds passed all these 
preprocessing steps will be included in final dataset. Besides of these, when 
inconsistent positive or negative classes were found at the merge from different 
sources, human inspection were done at the full records of that compound to decide 
whether it belongs to the positives or negatives (details in section 7.2.3). 
 
6.2.3 Positive and negative datasets  
We have done queries to get some lists from ChemIDplus344.  The record numbers of 
those lists are shown in Table 6-4. The screenshot of a query and toxicity report of a 
chemical are listed in Figure 6-2 and Figure 6-3. Our training and testing datasets 
were created by merge, duplication check, clean up from some lists from Table 6-4. 
For instance, in Study 1, the positive dataset were created from list 4 which contains 
8282 records. After duplication check, clean up and etc,   6581 compounds were used 
as positive training dataset. 
 
Table 6-4 Lists of query results and record numbers 
No List Number 
1 rat-oral-casno 13544 
2 rat-oral-over2000-casno 4936 
3 rat-oral-eq2000-casno 341 
4 rat-oral-less2000-casno 8282 
5 mouse-oral-casno 28014 
6 mouse-oral-over2000-casno 5676 
7 mouse-oral-less800-casno 12365 
8 mouse-oral-less2000-casno 24932 
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9 mouse-ip-casno 42149  
10 mouse-ip-less175-casno 13827 
11 mouse-ip-over1500-casno 3074 
12 clinical-trials-casno 3173 
13 rat-ip-casno 6201 
14 rat-iv-casno 3425 
15 clinicaltrials-rat oral  777 
16 clinicaltrials-rat oral <2000 442 
17 clinicaltrials-rat oral >2000 310 




Figure 6- 2 Screenshot of a ChemIDplus query344. 
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Figure 6- 3 Screenshot of a toxicity report sheet of Phenobarbital shown in 
ChemIDplus344 
 
As mentioned in previous paragraph, rat oral LD50 2000 mg/kg b.w. is selected as the 
value to separate the dataset in positives (acute toxic compounds) and negatives (non-
acute toxic compounds). In Study 1, only rat oral LD50 data are used. In Study 2 and 
3, some mouse LD50 data are added to increase the size of dataset for a better training. 
Previous studies have found good correlations can be found for LD50 from different 
administration routes and closely related species80, 335. For instance, between the rat 
oral LD50 and mouse oral LD50, there are several reported equations as listed in 
Table 6-5. 
 
Table 6-5 QSAR equations between mouse and rat oral LD50 
Equation Descriptions LD50 Ref. 
log LD50 Rat oral = 0.731+ 0.841 log LD50 Mouse oral n=3919;R2=0.75 1137.4 333 
log LD50 Mouse oral = -0.10+0.93log LD50 Rat oral n is between 506 
and 3,544; R2=0.76 
933.2 80  
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log (1/LD50 Rat oral)=1.01* log(1/LD50 Mouse oral) n=633, R2=0.89, 
s=0.29, F=5,288 
1855 335 






From these equations, rat oral LD50 2000 is found to correspond to mouse oral LD50 
1137.4, 933.2, 1855 and 943.9, respectively. It is too hard to decide because there are 
large variations. This is because many earlier analyses included quite a different 
numbers of data points, producing a substantial variation of parameters in QSAR 
equation. Anyhow, the first one seems to be more reasonable because it used the 
largest number of compounds for building the QSAR equations. To assure the quality 
of the new added data, certain gaps shall be kept from the criteria calculated from 
interspecies correlation equations. Certain level of accuracy, for instance, >=85%, 
shall be ensured to maintain the quality of training dataset (Figure 6-4). >=85% is 
chosen as a criteria because the desire SE and SP for the model are >85%. This idea 
could be further elaborated in the following example for adding some mouse oral 
LD50 data to training dataset. Rat oral LD50 2000mg/kg is the criteria to determine 
whether the compounds are acute toxic or not. So those compounds with a rat oral 
LD50 <2000mg/kg are classified as positives and those with LD50 >=2000mg/kg as 
negatives. Correspondingly the criterion for mouse oral LD50 data is 1137.4 
according to the first equation in Table 6-5. Use of the compounds with mouse LD50 
over 1137.4 as negatives will include around 72% true negatives and around 28% 
false negatives. This value 72% was calculated from the equation in Figure 6-4.  In 
the equation, the accuracy of using compounds with a mouse oral LD50 < 800 is 
evaluated by the acute toxic compounds rate as determined within those compounds 
with rat oral LD50 data.  The value 72% was thus calculated for mouse LD50>1137.4. 
Low level noise data are tolerable for SVM model because they will not change much 
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to the position of hyperplane that separate positives and negatives in training.  To 
ensure the quality of our added data, we need to leave a gap for it. Calculations show 
that all those compounds with a mouse oral LD50>=2000 have 85.8% accuracy to be 
really negatives. Therefore, compounds with a mouse oral >=2000 were added to 
negative training dataset in Study 2. Compounds with a mouse oral <800 were added 
to negative training dataset in Study 2. Compounds with mouse ip LD50<175 
and >=1500 were further added to positive and negative dataset with accuracy of 87% 
and 83% in Study 3, respectively. Finally, we will have 3 datasets for modeling as 
















mouse oral < 800 (%) =  
cpds ( mouse oral < 800)  AND 
cpds (rat oral < 2000)






Figure 6- 4 Accuracy of adding mouse data for training. 
 
Table 6- 6 SVM training datasets for acute toxicity studies 
Dataset Criteria 
(mg/kg) 
Data Source Number of 
positives 
Number of negatives 
1 2000 rat oral 6581 3817 
2 2000 rat oral + mouse oral 15564 7177 
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6.2.4 Independent testing datasets  
Two independent test sets from different sources were built for this project. At the 
first test set, 777 compounds were collected from a ChemIDplus344 list. At the second 
test set, a list of 67 unique traditional Chinese medicine (TCM) ingredients were 
collected from two Chinese books345, 346 were used. In that ChemIDplus344 list, there 
are 957 compounds with rat oral LD50 data out of the total 2615 compounds. The 
LD50 distributions of these 957 compounds are diverse. They have 7.2%, 10.8%, 
13.3%, 27.8%, 45.5% for LD50 categories: <50, 50-200, 200-500, 500-2000, >=2000 
respectively. These 957 compounds were further processed according to our clean-up 
procedures as shown in section 5.2.2 and 777 were left. They contain 442 compounds 
with LD50 <2000 and 335 compounds with a LD50 >=2000. This is the origin of the 
first independent test set.  As to the second test set, totally 217 ingredients were 
collected from the two books345, 346 and subjected to duplication check, structure 
check, descriptor calculation and assignment. Finally only 67 compounds were 
selected as the second independent test set. This is the origin of the second 
independent test set. 
 
6.3 Results and discussion 
 6.3.1 Overall prediction accuracies 
Software LibSVM158 is chosen to do the machine learning. Non-linear SVM separates 
the positives from the negatives with a hyperplane by mapping the input vectors to a 
higher dimensional feature space using a kernel function. The Radial Basis Function 
(RBF) kernel, widely adopted to consistently give better performance, was used in 
this study. In order to validate our studies, two types of validation tests were used. 
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The first one is 5-fold cross validation. The second one is independent evaluation 
studies. Optimally, the hard margin SVM was used with a gamma scan for best 
performance, as determined from the five-fold cross-validation results. Best gamma 
values were found at 6.25 for all three studies, whereby the SVM models gave 
prediction accuracy values averaging from 86.1% to 92.0% in SE and averaging 63.2% 
to 70.7% in SP (Table 6-7). The accuracies show a slight increase with the increase of 
size of the training dataset.  The detail results of 5-fold cross validation for study 1 
found at gamma = 6.25 is given in Table 6-8. At the first independent testing, 777 
compounds (442 positives and 335 negatives) were used. At the second independent 
testing, a list of 67 unique traditional Chinese medicine (TCM) ingredients was used. 
Independent testing using the 777 compounds shows 80.3% to 82.8% in SE, 71.0% to 
72.8% in SP, and 76.8% to 77.7% in overall prediction for the SVM models of these 3 
studies.  Independent testing using 67 unique TCM compounds shows 54.8% to 73.8% 
in SE, 40% to 44% in SP, 49.3% to 61.1% in overall accuracy for the SVM models of 
these 3 studies.  Finally, a model is then built with all the compounds at the best 
gamma. MDDR and PubChem database were screened with the model for 3 studies. 
Screening of the 139K MDDR compounds revealed 32.4% to 40.6% of the whole 
MDDR database as non acute toxic compounds and screening of the 13.6M PubChem 
compounds revealed 38.4% to 43.1% of the whole PubChem database as non acute 
toxic compounds (Table 6-7).  Table 6-9 lists non acute toxic rate of different type of 
chemicals based on those with rat data and our prediction results. Some chemicals in 
each class have been used for training already. They are consistent in results. 
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Table 6-7 SVM training datasets and model performance for acute toxicity studies.  
No Dataset   P and N 5 fold cross 
validation 
average results 
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Table 6-8 Performance of SVMs for classification of acute toxic and non-toxic 
compounds evaluated by 5-fold cross validation for study 1.  









TN FP SP 
(%) 
  
1 5265/1316 1124 192 85.41 3054/763 470 293 61.60 76.67 0.237 
2 5264/1317 1131 186 85.88 3053/764 495 269 64.79 78.14 0.271 
3 5265/1316 1152 164 87.54 3053/764  482 282 63.09 78.56 0.278 
4 5265/1316 1137 179 86.40 3054/763  467 296 61.21 77.15 0.246 
5 5265/1316 1120 196 85.11 3054/763 498 265 65.27 77.83 0.265 
avera
ge 
   
86.07 
   
63.19 77.70 0.259 
SD    0.957    1.827 0.760 0.0173 
SE    0.428    0.817 0.340 0.0077 
 
Table 6- 9 Non acute toxic rate of different types of chemicals 
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List  Description  Total  
Cpds with rat oral 
LD50  Screening Results  
Number of 
compounds  Rate  
Number of 
compounds Rate  
All  All Chemicals  384145  13548  39.0%  17.86M (PubChem)  
42.0%-
42.2%  





Recognized as Safe  
235  80  76.3%  105  73.3-78.1%  
PAFA  
List of Substances 
Added to Food in the 
U.S.  
3570  938  68.0%  2885  61.1%-63.8%  
PestName  Pesticides Common Names  1836  1075  32.7%  
579 37.7%-38.0%  
FIFR  EPA Pesticide List  1283  710  35.6%  
Clinical-




In a summary, all the SVM models from three studies showed reasonably good 
performance (63.2% to 70.7%) in predicting non-acute toxic compounds, and high 
accuracy rate (86.1% to 92.0%) in predicting acute toxic compounds. The overall 
accuracies (77.7% to 85.9%) are better than the reported ~70% accuracy QSAR 
methods (Table 6-2). However, caution needs to be raised about straightforward 
comparison of these results, which might be misleading because of the differences in 
the type, composition and diversity of compounds screened, and in the molecular 
descriptors, VS tools and their parameters used. The comparison cannot go beyond 
the statistics of accuracies and is only intended as a rough estimate of the VS 
performance of our SVM method.  
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6.3.2 Descriptors important for SVM  
In this study, a list of 522 descriptors were calculated using our own software 
MODLE136,118. These include composition based descriptors, electronic descriptors, 
and geometrical descriptors. They have shown good performance at previous studies 
in our group and this work. A number of other programs, e.g. DRAGON347, 
Chemistry Development Kit (CDK)119, 120 are available to calculate chemical 
descriptors. Table 6-10 lists descriptors used in various C-SAR programs80. They 
have shown some overlaps in classes of descriptors. Theoretically, physicochemical 
descriptors are responsible for identifying ADME-related factors, such as intestinal 
absorption, metabolism, tissue distribution, clearance, etc. Structural descriptors are 
responsible for the identification of ADME/Tox “biophores” or “toxicophores”. These 
can be represented as linear atom chains of variable length that are characteristic for 
active or inactive compounds. 3-D atom triplets and theoretical descriptors are a bit 
more complicated. They have a theoretical advantage in that they reflect the 
conformational flexibility of structures. They are supposed to be powerful at 
toxicophores that cannot be easily related to 2-D skeletons. Among those descriptors, 
logP, Abraham’s solvation parameters, Lipinski’s numbers of H-donors and H-
acceptors, Ertl’s topological polar surface area (TPSA), MW, pKa, and a few others 
are found to be important in many QSAR studies.  In a AB/C-SAR analysis based on 
physicochemical descriptors for 19,000 LD50 values (Iv-mouse), it is shown that 
charge and LogP turned out to be two most important descriptors. Compounds with 
permanent charges (>N+<, =N+<, >P+< and -S+<) are proved to be most toxic, 
whereas compounds with negative charges (bearing strong acid groups) proved to be 
least toxic80. When compared to 522 descriptors calculated from MODEL, many of 
those important descriptors are used but certain important descriptors like pKa, 
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logSW, TPSA are not included. Some simple structural descriptors are in MODEL but 
more complicated ones are missing. We expect better performance of SVM method 
with those descriptors added in the future. 
Table 6- 10 Descriptors used in various C-SAR programs (adopted from 
Zmuidinavicius, D. and etc80 ). 
 Descriptors Program 
Physchem LogP, LogSW (solubility) M-CASE, TSAR, AB 
 pKa, Ion form fractions, Solvation param.  AB 
Structural Linear and branched atom chains M-CASE, AB 
 Fragments and interactions AB 
 2D atom pairs SCAM, REX 
 3D atom triplets  SCAMPI  
Theoretical Topological, quantum chemical, shape, etc.  TSAR 
 
6.3.3 In vitro assays 
Acute systemic toxicity studies have been widely conducted on rodents to determine 
the relative health hazard of various chemicals and products. With increasing public 
awareness of animal welfare and the pressure of reducing the number of experimental 
animals, replacement of in vivo tests with in vitro alternatives has become a high 
priority and a number of methods have been proposed. A list of in vitro cytotoxicity 
assays in various cell lines have been explored, including human lung and dermal 
cells348, Chinese hamster ovary (CHO) cells349, rat hepatocytes350, 351, Hep-G2352, rat 
hepatoma-derived Fa32 cells338, rabbit cornea-derived cell line (SIRC-CVS)337, 
Neutral Red Uptake  (NRU) assay with both mouse fibroblast cell line (BALB/c 3T3) 
and primary normal human keratinoctyes (NHK)353, and others354-356. Some of these 
methods have claimed some good correlations (R>0.8) with LD50. However, further 
 Chapter 6 Development of a SVM Based Acute Toxicity Classification System 
 133 
studies have shown that there is only a relatively good correlation of around 50–60% 
between in vitro cytotoxic concentrations (IC50) and the rat oral LD50353. As 
compared to in vivo approaches, in vitra assays are much cheaper, easy made for HTS, 
and show clear mechanisms which is very important for late stage discovery. These 
are the big advantages of in vitra assays. 
 
Although single in vitro cytotoxicity assays itself cannot have a good prediction of 
LD50 alone because there are too many factors can impair the prediction of in vivo 
toxicity from basal cytotoxicity357, 358, an integrated systems could have much more 
potential.  Acute systemic toxicity can be broken down into a number of biokinetic, 
cellular, and molecular elements, each of which can be identified and quantified in 
appropriate models. These various elements may then be used in different 
combinations to model large numbers of toxic events to predict hazard and classify 
compounds359. Currently now both EU and US are putting considerable effort into 
developing and validating integrated systems: AcuteTox360-362 and ToxCast363, 364. In 
such systems, multiple in vitro assays are tested first, followed by a cytotoxicity assay 
to discriminate between toxic/hazardous (LD50<2,000 mg/kg) substances and 
substances not classified for acute toxicity (LD50>2,000 mg/kg), and at last 28-days 
repeated dose toxicity studies are carried out to identify compounds with LD50>2,000 
mg/kg. This represents the current most promising, yet to be further validated, non-
animal approach.  
 
6.3.4 LD50 classification and drug discovery 
The current study used rat oral LD50>=2000mg/kg b.w. as the criteria for 
classification of non acute and acute toxic chemicals. However, for different type of 
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chemicals and different projects, criteria could be different. For instance, food 
additive and anti cancer drugs certainly have different level of health safety 
requirements. In order to treat cancer, moderate toxic chemicals still stand a chance to 
be developed into anti cancer drugs if they have desired anti cancer effects. In this 
section, the distributions of rat oral LD50 data of different classes of chemicals 
(Table 6-11, Figure 6-5) are analyzed to give an estimation of LD50 criteria for 
different types of chemicals based on query results in ChemIDplus. 







Rate of chemicals in various LD50 ranges 
<50 50-200 200-500 
500-
2000 >=2000 
All All Chemicals 13548 0.127  0.104  0.138  0.299  0.390  







80 0.050  0.000  0.075  0.175  0.763  
PAFA 
List of Substances 
Added to Food in 
the U.S. 
938 0.048  0.029  0.062  0.220  0.680  
PestName Pesticides Common Names 1075 0.156  0.142  0.130  0.291  0.327  
FIFR EPA Pesticide List 710 0.155  0.110  0.118  0.308  0.356  
Clinical-Trials Clinicaltrials.gov 957 0.072  0.108  0.133  0.278  0.455  
S302 EPA Extremely 
Haz. Sub. 280 0.650  0.186  0.075  0.075  0.046  
ChEBI Chem Entities of Biological Interest 439 0.096  0.098  0.125  0.285  0.440  





930 0.082  0.081  0.131  0.285  0.454  
Genetox EPA GENetic TOXicology 1165 0.114  0.154  0.182  0.301  0.296  
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Figure 6- 5  Rat oral LD50 distributions of different type of chemicals. 
 
As shown in Figure 6-5, green line represents the rate of non acute toxic chemicals 
for different list of chemicals. The non-toxic rate of all chemicals is ~39%. GRASS 
and PAFA are the collections of food ingredients and additives. They are the most 
safe chemicals with 68-76% of chemicals are non acute toxic and around 90% of 
chemicals have a LD50 >=500. S302 is the list of extremely hazardous substance. As 
expected, 95% of chemicals are acute toxic. Pestcides are traditionally very toxic 
compounds. However, we can find that only 66% of chemicals are acute toxic. This 
shows that the development of safe but highly specific pesticides is the current trend. 
As to chemicals, IUclid (High Production Volume Chemicals reported by European 
Industry in the frame of the European existing chemicals risk assessment programme) 
contains 45% of non acute toxic chemicals. In the hazard assessment of these 
chemicals, the criteria of LD50>=2000 shall be chosen for non-acute toxic or unlikely 
acute hazardous chemicals. As to selection of drug candidates for clinic trials, the 
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efficacy as well as safety. Certain level of sacrifice in safety has to be taken at the cost 
of efficacy. In Figure 6-5, drug and clinical trial compounds have only about 45% of 
chemicals with a LD50>=2000. This is supported by the Chinese proverb ‘As a 
medicine, it is more or less toxic’. If we apply the same evaluation criteria 
(LD50>=2000 as no acute toxic) for drugs as food additives, it will lead to too much 
loss of potential candidates. This is certainly unacceptable.  Using LD50>=500 as 
criteria will reveal 71-74% of drug and clinical trials compounds. It could serve as 
better criteria for selection of candidates for clinical trials. As shown in Figure 6-5, 
red line represents the rate of highly toxic or highly hazardous chemicals for different 
list of chemicals. The highly-toxic rate of all chemicals is 12.7%. S302 (EPA 
Extremely Haz. Sub), pesticides, drug and clinical trial compounds, food additives 
have about 65%, 15.5%, 7%, 5% of chemicals that are highly toxic, respectively. 
These show that LD50<=50 can be used as a criteria for chemical screening to 
eliminate the extremely toxic compounds for drug discovery. Besides of these, other 
criteria (therapeutic index, the chronicity of the exposure and etc.) shall also be 
considered for the selected compounds. 
 
6.4 Conclusion 
Pharmaceutical companies and many administrative organizations, including US Food 
and Drug Administration, European Union member countries, are faced with big 
challenges of toxicity test for huge number of chemicals at reduced cost. While in 
vivo acute toxicity study is very costly, in terms of time, labour, compound synthesis 
and the sacrifice of large number of animals, legislation calls for the use of 
information from alternative non-animal approaches like in vitro methods and in 
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silico computational methods. As to in vitro methods, single cytoxicity assay cannot 
meet the need so US and EU are now spending a lot effort to build integrated systems 
(AcuteTox360-362 and ToxCast363, 364) including multiple in vitro assays, cytotoxicity 
assay and a 28-days repeated dose toxicity study. As to in silico approaches, QSAR 
based approaches remains the main solutions to prediction of acute toxicities.  New 
computational methods are sought to address the current issues and make a 
breakthrough in prediction of diverse classes of chemicals.  SVM has been explored 
in this study.  Not like C-SAR approach which split the diverse dataset into small 
subsets based on different health effects, SVM considers the whole dataset as a whole 
and tries to find the hyper-plane that separates the acute toxic and non toxic 
compounds. In order to find out the best hyper-plane, a big collection of training 
compounds with diverse toxicity mechanisms and a list of descriptors that can depict 
the complicated factors involved in acute toxicity are important. In this study we 
significantly increase the size of the training dataset by applying a method to absorb 
results from studies on other species and administrative routes. A list of 522 diverse 
types of descriptors calculated from MODEL software was used. Studies show that 
SVM models have better prediction accuracy (sensitivity ~90%, specificity ~70%, 
overall accuracy ~85% and independent testing ~70%) than previous studies in 
classification of acute and non acute toxic chemicals. This demonstrates the strength 
of SVM method in toxicity prediction.  However, the drawback of SVM approach is 
also obvious. It remains as a black box for end users, which does not give help on 
further investigations of toxicity mechanisms. Nevertheless, SVM and other ligand 
based approaches are anticipated to emerge as powerful predictive tools before a clear 
understanding of all toxic mechanisms related to acute toxicity.  
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In order for risk assessment of chemicals requiring higher safety administration like 
food additives, cosmetic, LD50>=2000 could be used. In order for selection of lead 
compound as drug candidate, LD50>=500 could be used. In order for chemical 
screening to eliminate the extremely toxic compounds, LD50<=50 could be used. 
Based on the administrative requirements of different chemicals, different SVM 
models based on different criteria could be built.  For a predictive method, a good 
performance with specificity >=85% and sensitivity >=85% and false positives<15% 
has been sought73.  For predictions of carcinogenicity, genetic toxicity, reproductive 
and developmental toxicity, and MRDD, this has been achieved. The emphasis of 
specificity over sensitivity can seem to conflict with the traditional cautious 
philosophy of regulators, but this position has to be taken at the screening of a large 
chemical library because otherwise it will result in a high false positive rate and 
maximizing regulatory controversy. Current SVM models can achieve good 
performance in terms of sensitivity (~90%) but specificity (~70%) does not meet the 
requirement for VS. We expect that an increase of negative dataset and optimization 
of descriptors can help to solve this.  
 
Finally, the limitation of acute toxicity and LD50 needs to be kept in mind that study 
of acute toxicity can only give a rough evaluation of toxic level of chemicals. Acute 
toxicity tests only short term toxicity and cannot address long term problems like 
bioaccumulation, carcinogenicity, teratogenicity, or mutagenic effects, or the impact 
on reproduction.  There is still a long way to do to bring a ‘safe compound’ from 
prediction into reality.  
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Chapter 7 Concluding Remarks  
7.1 Findings and merits 
With great increase of target and drug information, chemistry structures and functions 
added, TTD now contains 1,894 targets, 560 diseases and 5,028 drugs. In addition, 
IDAD was built to enhance the quick explore the compound activities of drugs. TTD 
has now really become an information portal like DrugBank and BindingDB. These 
three databases have different emphasis but can complement each other by providing 
comprehensive information about the primary targets and other drug data for the 
approved, clinical trial, and experimental drugs. From this update, we understand that 
the quality of database could be improved by integration of related information, cross 
linking to available databases, adding of database functions like customized download, 
similarity search. TTD was created in 2003 but the usage is low. Although this update 
does not provide the database novel information, it has made the database information 
more accessible to users. Moreover, by adding of activity information significant we 
improved the quality of TTD and further analysis of approved drugs and clinical trial 
compounds becomes possible.  
 
At the update, it was found that the mapping of chemicals to PubChem can help add 
important information, for example, the synonymous name of drugs. However, 
caution has to be taken at extracting information from other database which could 
contain errors. 
 
 When we started the project of SVM based VS in year 2005, SVM was still fairly 
used for VS. There were only a few reports. Now, SVM based VS system has been 
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gradually accepted by the end users. The putative negatives generation method plays 
an important role in it. This method greatly increased the performance of VS without 
losing much positive accuracy. It showed that at the study of chemistry and biological 
problems, certain assumption could be made to solve the problems although 
sometimes it may lead to certain degree of noises.  
 
As to acute toxicity study, the use of SVM method for classification is a new 
approach. Methods like QSARs are widely used but they generally have their 
applicability domain. But in SVM, the hyperplane was drawn by the influence of 
sufficiently large number of positive and negative compounds, and this hyperplane 
goes till infinity. Theoretically, there is no need to impose applicability domain in the 
SVM method employed in this study and the method is quite capable of finding novel 
hits as well. This is well support by good performance of SVM on true independent 
dataset. The use of SVM has greatly simplified the processes in building models.  
 
7.2 Limitations 
As to SVM based VS, a drawback of this approach is the possible inclusion of some 
undiscovered active compounds in the ‘inactive’ class, which may affect the 
capability of machine learning methods for identifying novel active compounds. 
However, such an adverse effect is expected to be relatively small and affordable for 
drug discovery.  
 
In acute toxicity study, it was desirable develop the models based on rat oral LD50, 
however, machine learning method is greatly influenced by the diversity of data 
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(compounds in this case) for building models. In order to increase the number of 
compounds for training, compounds with mouse LD50 data were converted. This 
would certainly lead to some errors. Moreover, as shown in the study of acute toxicity, 
Toxicities may be caused not by the compound originally administered, but rather by 
the results of biotransformations that the original compound undergoes. The discovery 
of toxicity based on the original compounds structures could have some limitations. 
Last SVM models can have a quick evaluation of compound toxicity but not able to 
give the exact mechanisms of acute toxicity. 
 
The compound descriptors of current SVM approach were calculated using our 
MODEL software. It provides more than 500 diverse types descriptors. However, 
these still do not cover all the important descriptors. As shown in the study of acute 
toxicity, some important descriptors used in QSARs like logS and PSA shall be 
included. 
 
SVM method is mainly used in this work. Although studies have shown that SVM 
show good performance at classification, other machine learning and structure based 
VS methods are expected to complement SVM approach to build consensus models 
for prediction.   
 
7.3 Suggestions for future studies 
For the future studies, there are a lot of work could be improved. 
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As to database development, as in the case of PDTD202, some of the VS methods and 
datasets118, 205 may also be included in TTD for facilitating target oriented drug lead 
discovery.  
As to SVM based VS system, studies on several targets have show good performance 
not only in screening hits, yield and enrichment factors but also a good potential in 
terms of prediction of novel type structures. However, experimental studies are 
needed to validate the approach. Based on this, we have formed extensive 
collaborations with several research groups on drug development. 
 
As to toxicity prediction, there are at least three works could be done. First, more 
compounds could be included to increase the diversity of datasets to further increase 
the prediction accuracy. Current accuracies for prediction of toxic and nontoxic 
compounds are 90% and 70%. For the toxic compounds prediction, it is enough but 
for non-toxic compounds it is still not enough. This is possibly due to the smaller 
number of non-toxic compounds. Further increase of non-toxic compounds could lead 
to increase expected rate. Second, toxicogenomics method has a great potential in 
predictive toxicology in terms of identification of biomarkers and probes of toxic 
mechanisms. They could be used to complement SVM based acute toxicity prediction 
system. At last, the improvement on metabolite prediction or integration with other 
metabolite prediction system seems highly desirable to significantly improve our 
prediction of assess toxic potential. 
 
These years have seen plenty of debates aimed to define which VS approach is 
the best one. However, this question remains with no conclusive answer. Each 
approach has its own advantages and drawbacks, and the choice of one or others 
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depends on the particular question faced by the medicinal chemist. In terms of 
performance, ligand based methods tend to present better enrichment factors and 
higher speed serving as a more efficient methodologies to remove non active 
compounds but target based method provides a more straightforward picture of 
interactions between the drug and molecular target and a better prediction in terms of 
novel structures.   
 
Now many people choose a synergistic, rational, synthetic combination of 
different approaches. Combined VS approach tends to include less costly approaches, 
usually ligand based VS, at the first stage, while the most demanding methods, 
usually docking, for the last stage when the original large compound library has been 
reduced to manageable size.  
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